BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004;350:2335-42. [DOI: 10.1056/nejmoa032691] [Cited by in Crossref: 7404] [Cited by in F6Publishing: 2440] [Article Influence: 435.5] [Reference Citation Analysis]
Number Citing Articles
1 Han J, Xiao D, Tan C, Zeng X, Hu H, Zeng S, Jiang Q, She L, Yao L, Li L, Tang L, Ma J, Huang J, Shen L. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Cancer Control 2020;27:1073274820902271. [PMID: 32107929 DOI: 10.1177/1073274820902271] [Reference Citation Analysis]
2 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
3 Karadurmus N, Sahin U, Basgoz BB, Arpaci F, Demirer T. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. World J Transplant 2016;6:675-81. [PMID: 28058217 DOI: 10.5500/wjt.v6.i4.675] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Maurya DK, Ayuzawa R, Doi C, Troyer D, Tamura M. Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo. J Environ Pathol Toxicol Oncol 2011;30:1-10. [PMID: 21609311 DOI: 10.1615/jenvironpatholtoxicoloncol.v30.i1.10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
5 Oka S, Shinohara S, Kuwata T, Takenaka M, Chikaishi Y, Hirai A, Ichiki Y, Shimajiri S, Aoki T, Tanaka F. The major thoracic vascular invasion of lung cancer. Ann Med Surg (Lond) 2017;20:13-8. [PMID: 28702181 DOI: 10.1016/j.amsu.2017.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
6 Louwen F, Muschol-Steinmetz C, Reinhard J, Reitter A, Yuan J. A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget 2012;3:759-73. [PMID: 22929622 DOI: 10.18632/oncotarget.595] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
7 Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11:155-80. [PMID: 21453286 DOI: 10.2174/156652311795684722] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
8 Hervieu C, Christou N, Battu S, Mathonnet M. The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. Cancers (Basel) 2021;13:1092. [PMID: 33806312 DOI: 10.3390/cancers13051092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Busceti CL, Marchitti S, Bianchi F, Di Pietro P, Riozzi B, Stanzione R, Cannella M, Battaglia G, Bruno V, Volpe M, Fornai F, Nicoletti F, Rubattu S. Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway. Front Pharmacol 2017;8:111. [PMID: 28352232 DOI: 10.3389/fphar.2017.00111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, O'Neal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, Frye SV, Zamboni WC, Pepe-Ranney C, Mani S, Kelly L, Redinbo MR. Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. Chem Biol 2015;22:1238-49. [PMID: 26364932 DOI: 10.1016/j.chembiol.2015.08.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 101] [Article Influence: 19.5] [Reference Citation Analysis]
11 Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007;25:4033-4042. [PMID: 17827451 DOI: 10.1200/jco.2007.11.3985] [Cited by in Crossref: 106] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
12 Kenneth TE, Kertes PJ. Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging 2006;1:451-66. [PMID: 18046922 DOI: 10.2147/ciia.2006.1.4.451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
13 Guérin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D. In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med 2012;18:83-94. [PMID: 22033674 DOI: 10.2119/molmed.2011.00120] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
14 Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 2015;33:1112-8. [PMID: 25691669 DOI: 10.1200/JCO.2014.58.4904] [Cited by in Crossref: 97] [Cited by in F6Publishing: 44] [Article Influence: 16.2] [Reference Citation Analysis]
15 Vaios EJ, Winter SF, Muzikansky A, Nahed BV, Dietrich J. Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neurooncol Adv 2020;2:vdaa031. [PMID: 32642690 DOI: 10.1093/noajnl/vdaa031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17:849-60. [PMID: 21131552 DOI: 10.1158/1078-0432.CCR-10-2144] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
17 Losa F, Barrios P, Salazar R, Torres-melero J, Benavides M, Massuti T, Ramos I, Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol 2014;16:128-40. [DOI: 10.1007/s12094-013-1053-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
18 Sargent DJ. Chemotherapy: Failure of bevacizumab in early-stage colon cancer. Nat Rev Clin Oncol 2011;8:10-1. [PMID: 21116295 DOI: 10.1038/nrclinonc.2010.205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 McCarville MB. New frontiers in pediatric oncologic imaging. Cancer Imaging 2008;8:87-92. [PMID: 18390392 DOI: 10.1102/1470-7330.2008.0012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Stein A. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer. 2014;14:761. [PMID: 25311943 DOI: 10.1186/1471-2407-14-761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
21 Heaton LL, López E, Maini PK, Fricker MD, Jones NS. Advection, diffusion, and delivery over a network. Phys Rev E Stat Nonlin Soft Matter Phys 2012;86:021905. [PMID: 23005783 DOI: 10.1103/PhysRevE.86.021905] [Cited by in Crossref: 28] [Cited by in F6Publishing: 4] [Article Influence: 3.1] [Reference Citation Analysis]
22 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
23 Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJ, Hospers GA, Hoekstra HJ. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Ann Surg Oncol 2012;19:620-6. [PMID: 21861214 DOI: 10.1245/s10434-011-2027-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
24 Regad T. Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) 2015;7:1758-84. [PMID: 26404379 DOI: 10.3390/cancers7030860] [Cited by in Crossref: 183] [Cited by in F6Publishing: 145] [Article Influence: 30.5] [Reference Citation Analysis]
25 Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 2009;9:112. [PMID: 19366444 DOI: 10.1186/1471-2407-9-112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
26 Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol. 2014;10:530-539. [PMID: 25048037 DOI: 10.1038/nrendo.2014.114] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
27 Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18:168-176. [PMID: 24557418 DOI: 10.1007/s10120-014-0351-5] [Cited by in Crossref: 146] [Cited by in F6Publishing: 126] [Article Influence: 20.9] [Reference Citation Analysis]
28 Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Invest New Drugs. 2012;30:1978-1983. [PMID: 21769636 DOI: 10.1007/s10637-011-9721-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Mizukami Y, Sasajima J, Ashida T, Kohgo Y. Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer. Int J Hematol 2012;95:125-30. [PMID: 22311464 DOI: 10.1007/s12185-012-1017-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) 2014;6:1753-68. [PMID: 25256831 DOI: 10.3390/cancers6031753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
31 Wang L, Jiang CF, Li DM, Ge X, Shi ZM, Li CY, Liu X, Yin Y, Zhen L, Liu LZ, Jiang BH. MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget 2016;7:2660-71. [PMID: 26673620 DOI: 10.18632/oncotarget.6545] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
32 Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs 2015;33:215-24. [PMID: 25363205 DOI: 10.1007/s10637-014-0176-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW. Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS One 2018;13:e0201809. [PMID: 30075027 DOI: 10.1371/journal.pone.0201809] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
34 Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [PMID: 19998273 DOI: 10.1002/cncr.24760] [Cited by in Crossref: 1205] [Cited by in F6Publishing: 1020] [Article Influence: 109.5] [Reference Citation Analysis]
35 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
36 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
37 Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer 2010;103:993-1000. [PMID: 20717111 DOI: 10.1038/sj.bjc.6605852] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
38 Li W, Zong S, Shi Q, Li H, Xu J, Hou F. Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: Involvement of HIF-1a, Claudin-4, and E-cadherin and Vimentin. Sci Rep. 2016;6:37534. [PMID: 27869227 DOI: 10.1038/srep37534] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
39 Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007;9:354-63. [PMID: 17452651 DOI: 10.1215/15228517-2007-006] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
40 Feng J, Zhao C, Wang L, Qu L, Zhu H, Yang Z, An G, Tian H, Shou C. Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy. Theranostics 2018;8:2094-106. [PMID: 29721065 DOI: 10.7150/thno.22069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
41 Kim JE, Kim KK, Kim SY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. J Cancer 2017;8:2263-8. [PMID: 28819429 DOI: 10.7150/jca.19582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, Rodriguez J, Bandres E, Garcia-Foncillas J. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol 2012;18:637-45. [PMID: 22363134 DOI: 10.3748/wjg.v18.i7.637] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
43 Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 2016;7:82473-81. [PMID: 27756883 DOI: 10.18632/oncotarget.12666] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
44 Johansson A, Ganss R. Remodeling of tumor stroma and response to therapy. Cancers (Basel) 2012;4:340-53. [PMID: 24213314 DOI: 10.3390/cancers4020340] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
45 Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J 2015;15:69-76. [PMID: 25069475 DOI: 10.1038/tpj.2014.40] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
46 Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009;101:1749-1757. [PMID: 19844231 DOI: 10.1038/sj.bjc.6605368] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 6.5] [Reference Citation Analysis]
47 Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther 2014;7:1927-32. [PMID: 25364263 DOI: 10.2147/OTT.S46457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
48 Hooglugt A, van der Stoel MM, Boon RA, Huveneers S. Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Front Oncol 2020;10:612802. [PMID: 33614496 DOI: 10.3389/fonc.2020.612802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Ariyan CE, Salem RR. Evolution in the treatment of metastatic colorectal carcinoma of the liver. World J Gastroenterol 2006;12:3253-8. [PMID: 16718848 DOI: 10.3748/wjg.v12.i20.3253] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
50 Nicodemus CF. Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy 2015;7:923-39. [PMID: 26314410 DOI: 10.2217/imt.15.57] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
51 Suetsugu T, Mori R, Futamura M, Fukada M, Tanaka H, Yasufuku I, Sato Y, Iwata Y, Imai T, Imai H, Tanaka Y, Okumura N, Matsuhashi N, Takahashi T, Yoshida K. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines. Oncol Rep 2021;45:27. [PMID: 33649846 DOI: 10.3892/or.2021.7978] [Reference Citation Analysis]
52 Wang J, Wang B, Bi J, Zhang C. Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med Oncol 2011;28 Suppl 1:S577-85. [PMID: 21046284 DOI: 10.1007/s12032-010-9734-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
53 Zulkifli A, Tan FH, Areeb Z, Stuart SF, Gomez J, Paradiso L, Luwor RB. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. Int J Mol Sci 2021;22:7114. [PMID: 34281166 DOI: 10.3390/ijms22137114] [Reference Citation Analysis]
54 Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, Purohit A, Reed MJ. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 2007;96:1368-76. [PMID: 17426705 DOI: 10.1038/sj.bjc.6603727] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc Natl Acad Sci U S A 2016;113:12532-7. [PMID: 27791128 DOI: 10.1073/pnas.1610258113] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
56 E J, Xing J, Gong H, He J, Zhang W. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. Tumour Biol 2015;36:1091-7. [PMID: 25326806 DOI: 10.1007/s13277-014-2667-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
57 Dewhirst MW, Secomb TW. Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer 2017;17:738-50. [PMID: 29123246 DOI: 10.1038/nrc.2017.93] [Cited by in Crossref: 249] [Cited by in F6Publishing: 195] [Article Influence: 62.3] [Reference Citation Analysis]
58 Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schüler Y, Kelly SP, Finucane C, Ellison D, Cebe-Suarez S, Ballmer-Hofer K. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer. 2008;44:1883-1894. [PMID: 18657413 DOI: 10.1016/j.ejca.2008.05.027] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
59 Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, Wahlberg E, Länne T, Sun B, Cao Y. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A. 2013;110:12018-12023. [PMID: 23818623 DOI: 10.1073/pnas.1301331110] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 9.9] [Reference Citation Analysis]
60 Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs 2014;32:851-9. [PMID: 24994097 DOI: 10.1007/s10637-014-0129-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
61 Zalewski A, Snook AE, Waldman SA. Stem cells as therapeutic targets in colorectal cancer. Per Med 2021;18:171-83. [PMID: 33565332 DOI: 10.2217/pme-2020-0099] [Reference Citation Analysis]
62 Buysschaert I, Schmidt T, Roncal C, Carmeliet P, Lambrechts D. Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med 2008;12:2533-51. [PMID: 19210754 DOI: 10.1111/j.1582-4934.2008.00515.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
63 Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014;5:99-103. [PMID: 24772337 DOI: 10.3978/j.issn.2078-6891.2014.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
64 Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, Chou WC, Tseng MH, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer 2011;105:975-82. [PMID: 21878936 DOI: 10.1038/bjc.2011.340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
65 Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542-1547. [PMID: 17114590 DOI: 10.1136/bjo.2006.098426] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 6.7] [Reference Citation Analysis]
66 Salmaggi A, Gaviani P, Botturi A, Lamperti E, Simonetti G, Ferrari D, Silvani A. Bevacizumab at recurrence in high-grade glioma. Neurol Sci 2011;32 Suppl 2:S251-3. [PMID: 21987287 DOI: 10.1007/s10072-011-0799-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
67 Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009;27:83-87. [PMID: 18563296 DOI: 10.1007/s10637-008-9146-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
68 Liu ZJ, Wang J, Wei XY, Chen P, Wang LC, Lin L, Sun BC, Li K. Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer. J Cancer Res Clin Oncol 2012;138:927-37. [PMID: 22331237 DOI: 10.1007/s00432-012-1167-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
69 Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19:1920-1925. [PMID: 23444216 DOI: 10.1158/1078-0432.ccr-12-2911] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
70 Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-35. [PMID: 20631635 DOI: 10.1097/JTO.0b013e3181e9a00f] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
71 Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). BMC Cancer 2016;16:69. [PMID: 26857924 DOI: 10.1186/s12885-016-2102-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
72 Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011;37:63-74. [PMID: 20570444 DOI: 10.1016/j.ctrv.2010.05.001] [Cited by in Crossref: 315] [Cited by in F6Publishing: 266] [Article Influence: 28.6] [Reference Citation Analysis]
73 Goel G, Sun W. Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014;33:445-57. [PMID: 25189717 DOI: 10.5732/cjc.014.10123] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
74 Nishigori N, Matsumoto M, Koyama F, Hayakawa M, Hatakeyayama K, Ko S, Fujimura Y, Nakajima Y. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy. PLoS One. 2015;10:e0143136. [PMID: 26580395 DOI: 10.1371/journal.pone.0143136] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
75 Ilic I, Jankovic S, Ilic M. Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One 2016;11:e0161912. [PMID: 27579775 DOI: 10.1371/journal.pone.0161912] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
76 Basu B, Eisen T. Perspectives in drug development for metastatic renal cell cancer. Target Oncol 2010;5:139-56. [PMID: 20689997 DOI: 10.1007/s11523-010-0149-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
77 Carcereny Costa E, Viñolas Segarra N, Gascón Vilaplana P. Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2008;10:198-203. [PMID: 18411192 DOI: 10.1007/s12094-008-0182-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
78 Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54:1194-202. [PMID: 16009693 DOI: 10.1136/gut.2004.062745] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
79 Seufferlein T, Ahn J, Krndija D, Lother U, Adler G, von Wichert G. Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal 2009;7:19. [PMID: 19678929 DOI: 10.1186/1478-811X-7-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
80 Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I. Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med 2010;8:19. [PMID: 20178639 DOI: 10.1186/1479-5876-8-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
81 Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Netw Open 2019;2:e1911750. [PMID: 31539075 DOI: 10.1001/jamanetworkopen.2019.11750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Hirashima T, Nagai T, Shigeoka H, Tamura Y, Yoshida H, Kawahara K, Kondoh Y, Sakai K, Hashimoto S, Fujishima M, Shiroyama T, Tamiya M, Morishita N, Suzuki H, Okamoto N, Kawase I. Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study. BMC Cancer 2014;14:770. [PMID: 25326267 DOI: 10.1186/1471-2407-14-770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
83 Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P; Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90:1316-21. [PMID: 16723358 DOI: 10.1136/bjo.2006.095190] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
84 Fujii M, Kobayakawa M, Saito K, Inano A, Morita A, Hasegawa M, Mukasa A, Mitsuhara T, Goto T, Yamaguchi S, Tamiya T, Nakatomi H, Oya S, Takahashi F, Sato T, Bakhit M, On Behalf Of The BeatNF Trial Investigators. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Curr Oncol 2021;28:726-39. [PMID: 33572546 DOI: 10.3390/curroncol28010071] [Reference Citation Analysis]
85 Gaustad JV, Simonsen TG, Smistad R, Wegner CS, Andersen LM, Rofstad EK. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging. BMC Cancer 2015;15:900. [PMID: 26573613 DOI: 10.1186/s12885-015-1918-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
86 Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K, Yuan Y. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther 2019;20:391-6. [PMID: 30307354 DOI: 10.1080/15384047.2018.1529120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol 2009;90:249-61. [PMID: 19563609 DOI: 10.1111/j.1365-2613.2009.00640.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
88 Desai AA, Stadler WM. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep 2005;7:116-22. [PMID: 15717945 DOI: 10.1007/s11912-005-0037-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
89 Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL, Ye JN. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf) 2020;8:179-91. [PMID: 32665850 DOI: 10.1093/gastro/goaa026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
90 Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008;205:491-501. [PMID: 18268040 DOI: 10.1084/jem.20072041] [Cited by in Crossref: 122] [Cited by in F6Publishing: 93] [Article Influence: 9.4] [Reference Citation Analysis]
91 Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007;97:1469-74. [PMID: 18040272 DOI: 10.1038/sj.bjc.6604053] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
92 Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol 2009;11:92-5. [PMID: 18757774 DOI: 10.1215/15228517-2008-071] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
93 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
94 Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941-951. [PMID: 16567391 DOI: 10.1084/jem.20052124] [Cited by in Crossref: 231] [Cited by in F6Publishing: 207] [Article Influence: 15.4] [Reference Citation Analysis]
95 Gornowicz A, Szymanowska A, Mojzych M, Czarnomysy R, Bielawski K, Bielawska A. The Anticancer Action of a Novel 1,2,4-Triazine Sulfonamide Derivative in Colon Cancer Cells. Molecules 2021;26:2045. [PMID: 33918514 DOI: 10.3390/molecules26072045] [Reference Citation Analysis]
96 Sasaki S, Watanabe T, Nakayama H. Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method. J Oncol 2013;2013:386906. [PMID: 23577026 DOI: 10.1155/2013/386906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
97 Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009;27:2848-2854. [PMID: 19380443 DOI: 10.1200/jco.2008.20.4552] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
98 Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer 2013;109:934-42. [PMID: 23860529 DOI: 10.1038/bjc.2013.376] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
99 Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012;181:376-9. [PMID: 22749677 DOI: 10.1016/j.ajpath.2012.06.006] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 10.0] [Reference Citation Analysis]
100 Sato S, Vasaikar S, Eskaros A, Kim Y, Lewis JS, Zhang B, Zijlstra A, Weaver AM. EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight 2019;4:132447. [PMID: 31661464 DOI: 10.1172/jci.insight.132447] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
101 Tong D, Liu F, Li W, Zhang W. The impacts of surgery of the primary cancer and radiotherapy on the survival of patients with metastatic rectal cancer. Oncotarget 2017;8:89214-27. [PMID: 29179513 DOI: 10.18632/oncotarget.19157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
102 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2015;121:1025-31. [PMID: 25417775 DOI: 10.1002/cncr.29169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
103 Mukai M, Komori K, Oka T. Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. J Atheroscler Thromb 2018;25:994-1002. [PMID: 30224607 DOI: 10.5551/jat.RV17027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
104 Yang Y, Zhang Y, Iwamoto H, Hosaka K, Seki T, Andersson P, Lim S, Fischer C, Nakamura M, Abe M, Cao R, Skov PV, Chen F, Chen X, Lu Y, Nie G, Cao Y. Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nat Commun 2016;7:12680. [PMID: 27580750 DOI: 10.1038/ncomms12680] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
105 Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol 2017;70:2536-51. [PMID: 29145954 DOI: 10.1016/j.jacc.2017.09.1096] [Cited by in Crossref: 145] [Cited by in F6Publishing: 109] [Article Influence: 36.3] [Reference Citation Analysis]
106 Chen SH, Tsai HL, Jiang JK, Sung YC, Huang CW, Yeh YM, Chen LT, Wang JY. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol. BMC Cancer 2019;19:640. [PMID: 31253124 DOI: 10.1186/s12885-019-5826-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Ladabaum U, Ferrandez A, Lanas A. Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev. 2010;19:2765-2776. [PMID: 20810603 DOI: 10.1158/1055-9965.epi-10-0530] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
108 Fenton BM, Paoni SF. Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiat Res 2009;171:606-14. [PMID: 19580496 DOI: 10.1667/RR1595.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
109 Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 2016;22:887-94. [PMID: 26811634 DOI: 10.3748/wjg.v22.i2.887] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
110 Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009;32:453-9. [PMID: 19487915 DOI: 10.1097/COC.0b013e3181925176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
111 Kaur H, Li JJ, Bay BH, Yung LY. Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLoS One 2013;8:e50964. [PMID: 23341879 DOI: 10.1371/journal.pone.0050964] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
112 Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther 2015;8:1111-8. [PMID: 26056475 DOI: 10.2147/OTT.S83952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
113 Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH. Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget 2015;6:7262-79. [PMID: 25788261 DOI: 10.18632/oncotarget.3225] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
114 Ocean AJ, Polite B, Christos P, Horvath L, Hamilton A, Matulich D, Chen HX, Sparano JA, Kindler HL. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer 2010;9:290-6. [PMID: 21208843 DOI: 10.3816/CCC.2010.n.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
115 Ciardiello F, Tejpar S, Papamichael D. Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. Target Oncol 2009;4:311-22. [PMID: 19915942 DOI: 10.1007/s11523-009-0129-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
116 Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ. VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci 2010;51:4273-81. [PMID: 20237249 DOI: 10.1167/iovs.09-4296] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
117 Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB 3rd. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Oncologist 2020;25:e798-807. [PMID: 31852811 DOI: 10.1634/theoncologist.2019-0437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
118 Nishi T, Hamamoto Y, Nagase M, Denda T, Yamaguchi K, Amagai K, Miyata Y, Yamanaka Y, Yanai K, Ishikawa T, Kuroki Y, Fujii H. Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). Oncol Lett. 2016;11:4049-4054. [PMID: 27313739 DOI: 10.3892/ol.2016.4532] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
119 Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open 2017;2:e000190. [PMID: 28761750 DOI: 10.1136/esmoopen-2017-000190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
120 Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, Livasy C, Ketelsen D, Nepal DB, Perou CM. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res. 2009;69:4621-4628. [PMID: 19458075 DOI: 10.1158/0008-5472.can-08-3402] [Cited by in Crossref: 72] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
121 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
122 Novillo A, Gaibar M, Romero-Lorca A, Gilsanz MF, Beltrán L, Galán M, Antón B, Malón D, Moreno A, Fernández-Santander A. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World J Gastroenterol 2020;26:1979-86. [PMID: 32390708 DOI: 10.3748/wjg.v26.i16.1979] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
123 Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT. Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nat Commun 2018;9:4112. [PMID: 30291241 DOI: 10.1038/s41467-018-06567-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
124 Coccolini F, Improta M, Cicuttin E, Catena F, Sartelli M, Bova R, De' Angelis N, Gitto S, Tartaglia D, Cremonini C, Ordonez C, Baiocchi GL, Chiarugi M. Surgical site infection prevention and management in immunocompromised patients: a systematic review of the literature. World J Emerg Surg 2021;16:33. [PMID: 34112231 DOI: 10.1186/s13017-021-00375-y] [Reference Citation Analysis]
125 Linkins LA. Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag 2008;4:279-87. [PMID: 18561503 DOI: 10.2147/vhrm.s2132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
126 Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837-42. [PMID: 17347807 DOI: 10.1007/s00417-007-0568-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
127 Kazemi-Lomedasht F, Pooshang-Bagheri K, Habibi-Anbouhi M, Hajizadeh-Safar E, Shahbazzadeh D, Mirzahosseini H, Behdani M. In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies. Iran J Basic Med Sci 2017;20:489-96. [PMID: 28656083 DOI: 10.22038/IJBMS.2017.8672] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
128 Hirte HW. Novel developments in angiogenesis cancer therapy. Curr Oncol 2009;16:50-4. [PMID: 19526086 DOI: 10.3747/co.v16i3.444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
129 Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012;18:6384-91. [PMID: 23104894 DOI: 10.1158/1078-0432.CCR-12-2223] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
130 Kriegl L, Jung A, Horst D, Rizzani A, Jackstadt R, Hermeking H, Gallmeier E, Gerbes AL, Kirchner T, Göke B, De Toni EN. Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PLoS One 2012;7:e51654. [PMID: 23284732 DOI: 10.1371/journal.pone.0051654] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
131 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
132 Ding C, Luo J, Fan X, Li L, Li S, Wen K, Feng J, Wu G. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels. J Exp Clin Cancer Res 2017;36:56. [PMID: 28420432 DOI: 10.1186/s13046-017-0524-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
133 Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-6. [PMID: 19920817 DOI: 10.1038/sj.bjc.6605417] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
134 Shibuya M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb Perspect Biol 2013;5:a009092. [PMID: 24086040 DOI: 10.1101/cshperspect.a009092] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
135 Jung K, Lee D, Lim HS, Lee SI, Kim YJ, Lee GM, Kim SC, Koh GY. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem 2011;286:14410-8. [PMID: 21345791 DOI: 10.1074/jbc.M111.228130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
136 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512-527. [PMID: 23313965 DOI: 10.1053/j.gastro.2013.01.002] [Cited by in Crossref: 395] [Cited by in F6Publishing: 351] [Article Influence: 49.4] [Reference Citation Analysis]
137 Frampas E, Maurel C, Remaud-Le Saëc P, Mauxion T, Faivre-Chauvet A, Davodeau F, Goldenberg DM, Bardiès M, Barbet J. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging 2011;38:2153-64. [PMID: 21858527 DOI: 10.1007/s00259-011-1903-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
138 Lindzen M, Lavi S, Leitner O, Yarden Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci U S A 2010;107:12559-63. [PMID: 20616021 DOI: 10.1073/pnas.1006218107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
139 Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999. [PMID: 16538219 DOI: 10.1038/sj.bjc.6603033] [Cited by in Crossref: 593] [Cited by in F6Publishing: 469] [Article Influence: 39.5] [Reference Citation Analysis]
140 Fiorentini G, Sarti D, Aliberti C, Carandina R, Mambrini A, Guadagni S. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol. 2017;8:190-202. [PMID: 28638789 DOI: 10.5306/wjco.v8.i3.190] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
141 Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6:297-305. [PMID: 19404270 DOI: 10.1038/nrgastro.2009.44] [Cited by in Crossref: 187] [Cited by in F6Publishing: 177] [Article Influence: 15.6] [Reference Citation Analysis]
142 Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54. [PMID: 20085937 DOI: 10.1200/JCO.2009.25.4482] [Cited by in Crossref: 174] [Cited by in F6Publishing: 68] [Article Influence: 15.8] [Reference Citation Analysis]
143 Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 2011;13:980-90. [PMID: 22028623 DOI: 10.1593/neo.11916] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
144 Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. AJNR Am J Neuroradiol 2019;40:1132-9. [PMID: 31248863 DOI: 10.3174/ajnr.A6110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
145 Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 2005;92:553-61. [PMID: 15668703 DOI: 10.1038/sj.bjc.6602374] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 4.4] [Reference Citation Analysis]
146 Tremolada G, Del Turco C, Lattanzio R, Maestroni S, Maestroni A, Bandello F, Zerbini G. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res 2012;2012:728325. [PMID: 22566995 DOI: 10.1155/2012/728325] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
147 Kurkjian C, Kim ES. Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf 2012;3:59-69. [PMID: 25083226 DOI: 10.1177/2042098611430109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011;5:117-29. [PMID: 21603247 DOI: 10.4137/CMO.S7232] [Cited by in Crossref: 83] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
149 Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19-30. [PMID: 22253552 DOI: 10.4137/CMO.S7432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
150 Loriot Y, Mordant P, Dorvault N, De la motte Rouge T, Bourhis J, Soria JC, Deutsch E. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. Br J Cancer 2010;103:347-53. [PMID: 20628392 DOI: 10.1038/sj.bjc.6605748] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
151 Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29:868-874. [PMID: 21189380 DOI: 10.1200/jco.2010.32.0770] [Cited by in Crossref: 129] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
152 Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A 2006;103:17426-31. [PMID: 17088539 DOI: 10.1073/pnas.0607959103] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
153 Guo L, Wen X, Hou Y, Sun R, Zhang L, Liu F, Liu J. Dihydroartemisinin inhibits endothelial cell migration via the TGF-β1/ALK5/SMAD2 signaling pathway. Exp Ther Med 2021;22:709. [PMID: 34007318 DOI: 10.3892/etm.2021.10141] [Reference Citation Analysis]
154 Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 2018;13:e0193640. [PMID: 29522543 DOI: 10.1371/journal.pone.0193640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Osorio M, Martinez E, Naranjo T, Castro C. Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review. Molecules 2020;25:E2270. [PMID: 32408538 DOI: 10.3390/molecules25102270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
156 Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 2008;134:381-7. [PMID: 17694324 DOI: 10.1007/s00432-007-0294-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
157 Nikanjam M, Liu S, Kurzrock R. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer 2016;139:2135-41. [PMID: 27389805 DOI: 10.1002/ijc.30262] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
158 Zimmerman MW, McQueeney KE, Isenberg JS, Pitt BR, Wasserloos KA, Homanics GE, Lazo JS. Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility. J Biol Chem 2014;289:5904-13. [PMID: 24403062 DOI: 10.1074/jbc.M113.480038] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
159 Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB. Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers (Basel) 2018;10:E526. [PMID: 30572654 DOI: 10.3390/cancers10120526] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
160 Paudyal B, Paudyal P, Shah D, Tominaga H, Tsushima Y, Endo K. Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. J Biomed Sci 2014;21:35. [PMID: 24780003 DOI: 10.1186/1423-0127-21-35] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
161 Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci. 2014;105:996-1001. [PMID: 24850362 DOI: 10.1111/cas.12451] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
162 Ambasta RK, Sharma A, Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell 2011;3:26. [PMID: 22082307 DOI: 10.1186/2045-824X-3-26] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
163 Johnson WR, Theeler BJ, Van Echo D, Young P, Kwok M. Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature. Case Rep Oncol 2018;11:281-8. [PMID: 29867436 DOI: 10.1159/000489085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
164 Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov. 2010;9:107-115. [PMID: 20118961 DOI: 10.1038/nrd3055] [Cited by in Crossref: 259] [Cited by in F6Publishing: 204] [Article Influence: 23.5] [Reference Citation Analysis]
165 dela Paz NG, Walshe TE, Leach LL, Saint-Geniez M, D'Amore PA. Role of shear-stress-induced VEGF expression in endothelial cell survival. J Cell Sci 2012;125:831-43. [PMID: 22399811 DOI: 10.1242/jcs.084301] [Cited by in Crossref: 123] [Cited by in F6Publishing: 101] [Article Influence: 13.7] [Reference Citation Analysis]
166 Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014;20:4263-75. [PMID: 24764664 DOI: 10.3748/wjg.v20.i15.4263] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
167 Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218:573-585. [PMID: 24491244 DOI: 10.1016/j.jamcollsurg.2013.12.013] [Cited by in Crossref: 150] [Cited by in F6Publishing: 119] [Article Influence: 18.8] [Reference Citation Analysis]
168 Meimarakis G, Angele M, Conrad C, Schauer R, Weidenhagen R, Crispin A, Giessen C, Preissler G, Wiedemann M, Jauch KW, Heinemann V, Stintzing S, Hatz RA, Winter H. Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone. Langenbecks Arch Surg 2013;398:265-76. [PMID: 23314791 DOI: 10.1007/s00423-012-1046-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
169 Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;13:611. [PMID: 24373251 DOI: 10.1186/1471-2407-13-611] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
170 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget 2016;7:34811-23. [PMID: 27166185 DOI: 10.18632/oncotarget.9187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
171 Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-7. [PMID: 19773379 DOI: 10.1158/1078-0432.CCR-09-0058] [Cited by in Crossref: 126] [Cited by in F6Publishing: 54] [Article Influence: 10.5] [Reference Citation Analysis]
172 Neugut AI, Becker DJ, Insel BJ, Hershman DL. Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer. J Oncol Pract 2012;8:156-63. [PMID: 22942809 DOI: 10.1200/JOP.2011.000371] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
173 Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007;91:1230-3. [PMID: 17475701 DOI: 10.1136/bjo.2007.117309] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
174 Wright KD, Gajjar A. New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009;25:1275-82. [PMID: 19212772 DOI: 10.1007/s00381-009-0809-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
175 Yanmaz MT, Guner SI, Satılmıs B, Akyol H, Aydın MA. Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Med Oncol 2014;31:276. [PMID: 25294426 DOI: 10.1007/s12032-014-0276-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Bao L, You B, Shi S, Shan Y, Zhang Q, Yue H, Zhang J, Zhang W, Shi Y, Liu Y, Wang X, Liu D, You Y. Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene. 2018;37:2873-2889. [PMID: 29520105 DOI: 10.1038/s41388-018-0183-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
177 Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther 2015;8:243-9. [PMID: 25670906 DOI: 10.2147/OTT.S75722] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb Mol Case Stud 2016;2:a001016. [PMID: 27626067 DOI: 10.1101/mcs.a001016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
179 Deplanque G, Madhusudan S, Jones PH, Wellmann S, Christodoulos K, Talbot DC, Ganesan TS, Blann A, Harris AL. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer 2004;91:1645-50. [PMID: 15354209 DOI: 10.1038/sj.bjc.6602126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
180 Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol 2015;22:e305-15. [PMID: 26300681 DOI: 10.3747/co.22.2603] [Reference Citation Analysis]
181 Boas FE, Bodei L, Sofocleous CT. Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes. J Nucl Med 2017;58:104S-11S. [PMID: 28864605 DOI: 10.2967/jnumed.116.187229] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
182 Bueno MJ, Mouron S, Quintela-Fandino M. Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach. Br J Cancer 2017;116:1119-25. [PMID: 28301873 DOI: 10.1038/bjc.2017.69] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
183 Tsavaris N, Voutsas IF, Kosmas C, Gritzapis AD, Baxevanis CN. Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients. Invest New Drugs 2012;30:395-402. [PMID: 20820907 DOI: 10.1007/s10637-010-9533-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
184 Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013;5:133-41. [PMID: 23450196 DOI: 10.1177/1758834012467661] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
185 Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH. Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med 2016;3:9-21. [PMID: 27275004 DOI: 10.1016/j.nhtm.2016.03.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
186 Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2011;10:1306-1314. [PMID: 20948320 DOI: 10.4161/cbt.10.12.13582] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
187 Kitano H, Kitadai Y, Teishima J, Yuge R, Shinmei S, Goto K, Inoue S, Hayashi T, Sentani K, Yasui W, Matsubara A. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma. Cancer Med 2017;6:2308-20. [PMID: 28834289 DOI: 10.1002/cam4.1124] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
188 Ribatti D, Annese T, Ruggieri S, Tamma R, Crivellato E. Limitations of Anti-Angiogenic Treatment of Tumors. Transl Oncol 2019;12:981-6. [PMID: 31121490 DOI: 10.1016/j.tranon.2019.04.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
189 Wang T, Hu K, Ren J, Zhu Q, Wu G, Peng G. Polymorphism of VEGF-2578C/A associated with the risk and aggressiveness of nasopharyngeal carcinoma in a Chinese population. Mol Biol Rep 2010;37:59-65. [PMID: 19340604 DOI: 10.1007/s11033-009-9526-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
190 Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA. 2007;104:3478-3483. [PMID: 17360669 DOI: 10.1073/pnas.0611492104] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 6.3] [Reference Citation Analysis]
191 Danciu OC, Rayani S, Michals EA, Villano JL. Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Med Oncol 2012;29:2619-22. [PMID: 22209841 DOI: 10.1007/s12032-011-0148-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Ramcharan KS, Lip GY, Stonelake PS, Blann AD. Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer. Br J Cancer 2014;111:1742-9. [PMID: 25211664 DOI: 10.1038/bjc.2014.491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
193 Jackson DB, Sood AK. Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol 2011;8:735-41. [PMID: 21989071 DOI: 10.1038/nrclinonc.2011.151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
194 Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol. 2013;19:8474-8488. [PMID: 24379565 DOI: 10.3748/wjg.v19.i46.8474] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
195 Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y, Tanaka S, Yasui W, Chayama K. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. Cancer Sci 2016;107:601-8. [PMID: 26865419 DOI: 10.1111/cas.12907] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
196 Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70. [PMID: 24765614 DOI: 10.3389/fonc.2014.00070] [Cited by in Crossref: 157] [Cited by in F6Publishing: 146] [Article Influence: 22.4] [Reference Citation Analysis]
197 Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 2010;10:397. [PMID: 20673348 DOI: 10.1186/1471-2407-10-397] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
198 Metges JP, Lebot MA, Faroux R, Riaud F, Gamelin E, Capitain O, Guérin Meyer V, Leynia P, Douillard JY, Senellart H, Rochard S, Louvigné C, Campion L, Dupuis O, Grollier C, Achour NA, Person B, Raoul JL, Boucher E, Bertrand C, Ramée JF, Guivarch L, Etienne PL, Roussel S, Desclos H, Julien MN, Labarre MI, Klein V, Bessard R, Stampfli C, Royet F, Faycal J, Gouva S, Le Bihan G, Couturier M, Gourlaouen A, Bertholom C, Porneuf M, Jobard E, Peguet E, Grasset D, Bouret JF, Bicheler V, Ulvoas A, Miglianico L, Chouzenoux C, Deguiral P, Derenne L, Martin D, Langlet PM, Bodin C, Rossi V, Barré S, Cojocarasu O, Naveau Ploux C, Vidal AM, Cumin I, Egreteau J, Brouard A, Matysiak Budnik T, Thomaré P, Le Bris Michel AS, Piriou G, Largeau R, Elhannani C, Crespeau E, Suberville F, Bourgeois H, Riche C, Lagadec DD, Marhuenda F, Grudé F. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire). Oncologie (Paris) 2014;16:267-76. [PMID: 26190928 DOI: 10.1007/s10269-014-2391-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Aprile G, Bonotto M, Ongaro E, Pozzo C, Giuliani F. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs. 2013;73:2003-2015. [PMID: 24277700 DOI: 10.1007/s40265-013-0154-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
200 Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs Aging 2011;28:83-91. [PMID: 21155618 DOI: 10.2165/11584710-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
201 Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27:4096-4102. [PMID: 19636002 DOI: 10.1200/jco.2009.21.852] [Reference Citation Analysis]
202 Doloff JC, Khan N, Ma J, Demidenko E, Swartz HM, Jounaidi Y. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine. Curr Cancer Drug Targets 2009;9:777-88. [PMID: 19754361 DOI: 10.2174/156800909789271503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
203 Ciombor KK, Berlin J. Aflibercept--a decoy VEGF receptor. Curr Oncol Rep 2014;16:368. [PMID: 24445500 DOI: 10.1007/s11912-013-0368-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
204 Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci 2012;103:626-31. [PMID: 22212856 DOI: 10.1111/j.1349-7006.2011.02195.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
205 Stein A, Hiemer S, Schmoll H. Adjuvant Therapy for Early Colon Cancer: Current Status. Drugs 2011;71:2257-75. [DOI: 10.2165/11594490-000000000-00000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
206 Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, Zhang T. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013;11:306. [PMID: 24283603 DOI: 10.1186/1477-7819-11-306] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
207 Oshima T, Masuda M. Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today 2012;42:313-27. [PMID: 22127535 DOI: 10.1007/s00595-011-0065-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
208 Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74:100-13. [PMID: 17532010 DOI: 10.1016/j.mvr.2007.03.004] [Cited by in Crossref: 127] [Cited by in F6Publishing: 113] [Article Influence: 9.1] [Reference Citation Analysis]
209 Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765-2772. [PMID: 18636296 DOI: 10.1245/s10434-008-0035-7] [Cited by in Crossref: 112] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
210 Zhang L, Takara K, Yamakawa D, Kidoya H, Takakura N. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Cancer Sci 2016;107:36-44. [PMID: 26475217 DOI: 10.1111/cas.12836] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
211 Adamcic U, Skowronski K, Peters C, Morrison J, Coomber BL. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia 2012;14:612-23. [PMID: 22904678 DOI: 10.1593/neo.11948] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
212 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Venkatramani R, Malogolowkin M, Davidson TB, May W, Sposto R, Mascarenhas L. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS One 2013;8:e68416. [PMID: 23894304 DOI: 10.1371/journal.pone.0068416] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
214 Zhou H, Chen M, Zhao D. Longitudinal MRI evaluation of intracranial development and vascular characteristics of breast cancer brain metastases in a mouse model. PLoS One 2013;8:e62238. [PMID: 23638013 DOI: 10.1371/journal.pone.0062238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
215 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020;11:761-808. [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
216 Zhou Q, Yu B, Anderson C, Huang ZP, Hanus J, Zhang W, Han Y, Bhattacharjee PS, Srinivasan S, Zhang K, Wang DZ, Wang S. LncEGFL7OS regulates human angiogenesis by interacting with MAX at the EGFL7/miR-126 locus. Elife 2019;8:e40470. [PMID: 30741632 DOI: 10.7554/eLife.40470] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
217 Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process? J Geriatr Oncol. 2014;5:40-48. [PMID: 24484717 DOI: 10.1016/j.jgo.2013.11.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
218 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group., Cancer Research UK., Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO)., Australasian Gastro-Intestinal Trials Group (AGITG)., Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9] [Cited by in Crossref: 1305] [Cited by in F6Publishing: 430] [Article Influence: 100.4] [Reference Citation Analysis]
219 Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E752. [PMID: 28368335 DOI: 10.3390/ijms18040752] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
220 Ranieri G, Laface C, Laforgia M, De Summa S, Porcelli M, Macina F, Ammendola M, Molinari P, Lauletta G, Di Palo A, Rubini G, Ferrari C, Gadaleta CD. Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. Front Oncol 2020;10:590707. [PMID: 33224885 DOI: 10.3389/fonc.2020.590707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
221 Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, Gruenberger T, Brostjan C. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer. 2012;107:961-966. [PMID: 22850548 DOI: 10.1038/bjc.2012.342] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
222 Beretta GD, Petrelli F, Stinco S, Cabiddu M, Ghilardi M, Squadroni M, Borgonovo K, Barni S. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol. 2013;30:486. [PMID: 23400961 DOI: 10.1007/s12032-013-0486-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
223 Larkin JM, Kipps EL, Powell CJ, Swanton C. Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol 2009;1:15-27. [PMID: 21789110 DOI: 10.1177/1758834009338430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
224 Onoda N, Nakamura M, Aomatsu N, Noda S, Kashiwagi S, Hirakawa K. Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors. World J Surg 2014;38:688-95. [PMID: 24357248 DOI: 10.1007/s00268-013-2409-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
225 Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 2016;7:78269-80. [PMID: 27861157 DOI: 10.18632/oncotarget.13412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
226 Van der Veldt AA, Lammertsma AA, Smit EF. Scheduling of anticancer drugs: timing may be everything. Cell Cycle. 2012;11:4339-4343. [PMID: 23032365 DOI: 10.4161/cc.22187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
227 Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G 2nd, Camp ER, Ellis LM. Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol Cancer Ther 2008;7:3064-70. [PMID: 18790786 DOI: 10.1158/1535-7163.MCT-08-0615] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
228 Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015;21:7281-8. [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
229 Chen QY, Liu Y, Luesch H. Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity. ACS Med Chem Lett 2011;2:861-5. [PMID: 22081789 DOI: 10.1021/ml200176m] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
230 Lakatos G, Köhne CH, Bodoky G. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status.Cancer Metastasis Rev. 2020;39:1143-1157. [PMID: 32648137 DOI: 10.1007/s10555-020-09913-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA;  ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428-436. [PMID: 21737787 DOI: 10.1161/circresaha.111.245993] [Cited by in Crossref: 353] [Cited by in F6Publishing: 177] [Article Influence: 35.3] [Reference Citation Analysis]
232 Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012;136:169-178. [PMID: 23001754 DOI: 10.1007/s10549-012-2256-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
233 Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, Duda DG, Jain RK, Fukumura D. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med. 2016;8:360ra135. [PMID: 27733559 DOI: 10.1126/scitranslmed.aaf5219] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 25.8] [Reference Citation Analysis]
234 Corrò C, Dutoit V, Koessler T. Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers (Basel) 2021;13:1374. [PMID: 33803620 DOI: 10.3390/cancers13061374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011;76:87-93. [PMID: 21205697 DOI: 10.1212/WNL.0b013e318204a3af] [Cited by in Crossref: 64] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
236 Lin R, Huang J, Wang L, Li Y, Lipowska M, Wu H, Yang J, Mao H. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging. Biomater Sci 2018;6:1517-25. [PMID: 29652061 DOI: 10.1039/c8bm00225h] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
237 Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 2017;18:946-57. [PMID: 28549783 DOI: 10.1016/S1470-2045(17)30355-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 50] [Article Influence: 27.8] [Reference Citation Analysis]
238 Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol. 2010;2:380-389. [PMID: 21160889 DOI: 10.4251/wjgo.v2.i10.380] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
239 Poterucha T, Burnette B, Jatoi A. A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med Oncol 2012;29:1005-9. [PMID: 21399996 DOI: 10.1007/s12032-011-9894-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
240 Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108:1566-1570. [PMID: 23558891 DOI: 10.1038/bjc.2013.140] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
241 Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013;23:104-13. [PMID: 23290365 DOI: 10.1016/j.tcm.2012.09.008] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
242 Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, Smith RG, LaFleur DW, Barbas CF 3rd, Hilbert DM, Kiener PA, Roschke VV. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012;4:600-13. [PMID: 22864384 DOI: 10.4161/mabs.21227] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
243 Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, Karabulut S, Sakar B, Disci R. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Med Oncol 2013;30:679. [PMID: 23921648 DOI: 10.1007/s12032-013-0679-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
244 Chen K, Gong Y, Zhang Q, Shen Y, Zhou T. Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore) 2016;95:e5221. [PMID: 27861344 DOI: 10.1097/MD.0000000000005221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013;31:373-9. [PMID: 23248256 DOI: 10.1200/JCO.2012.42.1529] [Cited by in Crossref: 149] [Cited by in F6Publishing: 43] [Article Influence: 16.6] [Reference Citation Analysis]
246 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Ann Med Surg (Lond) 2017;20:19-25. [PMID: 28702182 DOI: 10.1016/j.amsu.2017.06.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
247 Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer 2012;107:1277-85. [PMID: 22990652 DOI: 10.1038/bjc.2012.406] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
248 Klupp F, Kahlert C, Franz C, Halama N, Schleussner N, Wirsik NM, Warth A, Schmidt T, Ulrich AB. Granulin: An Invasive and Survival-Determining Marker in Colorectal Cancer Patients. Int J Mol Sci 2021;22:6436. [PMID: 34208547 DOI: 10.3390/ijms22126436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009;115:3571-80. [PMID: 19536893 DOI: 10.1002/cncr.24412] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.8] [Reference Citation Analysis]
250 Smaglo BG, Hwang J. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013;4:299-307. [PMID: 23997941 DOI: 10.3978/j.issn.2078-6891.2013.030] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
251 Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015;15:786. [PMID: 26497654 DOI: 10.1186/s12885-015-1712-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
252 Glynne-Jones R, Kronfli M. Locally advanced rectal cancer: a comparison of management strategies. Drugs. 2011;71:1153-1177. [PMID: 21711061 DOI: 10.2165/11591330-000000000-00000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
253 Tang N, Wang Z. Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients. Onco Targets Ther 2016;9:4671-9. [PMID: 27536131 DOI: 10.2147/OTT.S110339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
254 Fiala O, Finek J, Buchler T, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Liska V, Topolcan O. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study. Target Oncol 2015;10:549-55. [PMID: 25875421 DOI: 10.1007/s11523-015-0365-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
255 Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 2016;37:127-40. [PMID: 26566626 DOI: 10.1007/s13277-015-4408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
256 Yang J, Liu R, Ektare V, Stephens J, Shelbaya A. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. Appl Health Econ Health Policy 2021;19:605-18. [PMID: 33506318 DOI: 10.1007/s40258-021-00637-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
257 Marquardt F, Rödel F, Capalbo G, Weiss C, Rödel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol. 2009;185:371-378. [PMID: 19506820 DOI: 10.1007/s00066-009-1936-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
258 Jang JY, Choi SY, Park I, Park DY, Choe K, Kim P, Kim YK, Lee BJ, Hirashima M, Kubota Y, Park JW, Cheng SY, Nagy A, Park YJ, Alitalo K, Shong M, Koh GY. VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis. EMBO Mol Med 2017;9:750-69. [PMID: 28438786 DOI: 10.15252/emmm.201607341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
259 Chakra CHS, Rajendar V, Rao KV, Kumar M. Enhanced antimicrobial and anticancer properties of ZnO and TiO2 nanocomposites. 3 Biotech 2017;7:89. [PMID: 28550407 DOI: 10.1007/s13205-017-0731-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
260 Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009;6:259-65. [PMID: 19390552 DOI: 10.1038/nrclinonc.2009.38] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
261 Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 2008;4:1367-70. [PMID: 19337443 DOI: 10.2147/tcrm.s3960] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
262 Pereira SS, Oliveira S, Monteiro MP, Pignatelli D. Angiogenesis in the Normal Adrenal Fetal Cortex and Adrenocortical Tumors. Cancers (Basel) 2021;13:1030. [PMID: 33804534 DOI: 10.3390/cancers13051030] [Reference Citation Analysis]
263 Gil-Bazo I. Novel translational strategies in colorectal cancer research. World J Gastroenterol 2007;13:5902-10. [PMID: 17990355 DOI: 10.3748/wjg.v13.i44.5902] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
264 Kobayashi H, Yamamoto H, Miyata H, Gotoh M, Kotake K, Sugihara K, Toh Y, Kakeji Y, Seto Y. Impact of adherence to board-certified surgeon systems and clinical practice guidelines on colon cancer surgical outcomes in Japan: A questionnaire survey of the National Clinical Database. Ann Gastroenterol Surg 2020;4:283-93. [PMID: 32490342 DOI: 10.1002/ags3.12327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
265 Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012;14:285-94. [PMID: 22544560 DOI: 10.1007/s11912-012-0242-z] [Cited by in Crossref: 132] [Cited by in F6Publishing: 95] [Article Influence: 14.7] [Reference Citation Analysis]
266 Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
267 McLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y, Franci C, Lang D, Pali E, Lasaga J, Low C, Zhao F, Chang B, Gururaja TL, Xu W, Baluom M, Sweeny D, Carroll D, Sran A, Thota S, Parmer M, Romane A, Clemens G, Grossbard E, Qu K, Jenkins Y, Kinoshita T, Taylor V, Holland SJ, Argade A, Singh R, Pine P, Payan DG, Hitoshi Y. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136:99-113. [PMID: 19609559 DOI: 10.1007/s00432-009-0641-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
268 Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther 2013;6:1393-8. [PMID: 24124381 DOI: 10.2147/OTT.S51164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 2014;11:413-31. [PMID: 24913374 DOI: 10.1038/nrclinonc.2014.89] [Cited by in Crossref: 182] [Cited by in F6Publishing: 150] [Article Influence: 26.0] [Reference Citation Analysis]
270 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017;7:CD008398. [PMID: 28752564 DOI: 10.1002/14651858.CD008398.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
271 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
272 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. [PMID: 26775688 DOI: 10.1038/nrd.2015.17] [Cited by in Crossref: 406] [Cited by in F6Publishing: 340] [Article Influence: 81.2] [Reference Citation Analysis]
273 Oguntade AS, Al-Amodi F, Alrumayh A, Alobaida M, Bwalya M. Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Canc Inst 2021;33:15. [PMID: 34212275 DOI: 10.1186/s43046-021-00072-6] [Reference Citation Analysis]
274 Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer 2016;114:1003-11. [PMID: 27002940 DOI: 10.1038/bjc.2016.74] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
275 Cheung FP, Alam NZ, Wright GM. The Past, Present and Future of Pulmonary Metastasectomy: A Review Article. Ann Thorac Cardiovasc Surg 2019;25:129-41. [PMID: 30971647 DOI: 10.5761/atcs.ra.18-00229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
276 Nokihara H, Yamamoto N, Yamada Y, Yamada K, Hirata T, Goto Y, Tanioka M, Ikeda Y, Tamura T. A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol 2012;70:559-65. [PMID: 22878519 DOI: 10.1007/s00280-012-1932-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
277 Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? Curr Oncol Rep. 2012;14:249-256. [PMID: 22434313 DOI: 10.1007/s11912-012-0232-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
278 Cereda MG, Parolini B, Bellesini E, Pertile G. Surgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space. Graefes Arch Clin Exp Ophthalmol 2010;248:37-47. [PMID: 19802629 DOI: 10.1007/s00417-009-1201-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
279 Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010;128:1-36. [PMID: 20546782 DOI: 10.1016/j.pharmthera.2010.04.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
280 Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, Mikkelsen T, Fisher JD; New Approaches to Brain Tumor Therapy CNS Consortium. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol 2005;7:246-53. [PMID: 16053699 DOI: 10.1215/S1152851704000869] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
281 Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, D'Incalci M, Ryan AJ, Giavazzi R. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia 2009;11:1155-64. [PMID: 19881951 DOI: 10.1593/neo.09866] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
282 Wang HY, Chu JF, Zhang P, Wang JQ, Yan Z, Yao SN, Yao ZH, Liu YY. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma. Onco Targets Ther. 2020;13:1561-1568. [PMID: 32110053 DOI: 10.2147/ott.s235349] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
283 Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 2015;106:883-90. [PMID: 25867139 DOI: 10.1111/cas.12674] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
284 Segal E, Pan H, Benayoun L, Kopečková P, Shaked Y, Kopeček J, Satchi-Fainaro R. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011;32:4450-63. [PMID: 21429572 DOI: 10.1016/j.biomaterials.2011.02.059] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
285 Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 2015;33:911-20. [PMID: 25990659 DOI: 10.1007/s10637-015-0251-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
286 Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601-13. [PMID: 18780827 DOI: 10.1148/radiol.2492071659] [Cited by in Crossref: 236] [Cited by in F6Publishing: 195] [Article Influence: 18.2] [Reference Citation Analysis]
287 Bécouarn Y, Cany L, Pulido M, Beyssac R, Texereau P, Le Morvan V, Béchade D, Brunet R, Aitouferoukh S, Lalet C, Mathoulin-Pélissier S, Fonck M, Robert J. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes 2014;7:260. [PMID: 24758527 DOI: 10.1186/1756-0500-7-260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
288 Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28:193-201. [PMID: 19949019 DOI: 10.1200/jco.2009.22.4279] [Cited by in Crossref: 107] [Cited by in F6Publishing: 67] [Article Influence: 8.9] [Reference Citation Analysis]
289 Stantz KM, Cao M, Cao N, Liang Y, Miller KD. Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT. Mol Imaging Biol 2011;13:1183-95. [PMID: 20957443 DOI: 10.1007/s11307-010-0441-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
290 López RI, Castro JL, Cedeño H, Cisneros D, Corrales L, González-Herrera I, Lima-Pérez M, Prestol R, Salinas R, Soriano-García JL, T Zavala A, Zetina LM, Zúñiga-Orlich CE. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016. ESMO Open 2018;3:e000315. [PMID: 29636987 DOI: 10.1136/esmoopen-2017-000315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
291 Chen H, Ding X, Gao Y, Jiang X, Liu X, Chen Y, Gao J, Zhou X, Cai Z, Sun Q. Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3. MAbs 2013;5:956-61. [PMID: 23995616 DOI: 10.4161/mabs.26239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
292 Izzedine H. Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol 2014;2014:143426. [PMID: 25210627 DOI: 10.1155/2014/143426] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
293 Li H, Ma SQ, Huang J, Chen XP, Zhou HH. Roles of long noncoding RNAs in colorectal cancer metastasis. Oncotarget 2017;8:39859-76. [PMID: 28418892 DOI: 10.18632/oncotarget.16339] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 17.3] [Reference Citation Analysis]
294 Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69:58-66. [PMID: 20078613 DOI: 10.1111/j.1365-2125.2009.03556.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
295 Goh V, Rodriguez-Justo M, Engledow A, Shastry M, Endozo R, Peck J, Meagher M, Taylor SA, Halligan S, Groves AM. Assessment of the metabolic flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method. Eur Radiol 2012;22:1687-92. [PMID: 22527369 DOI: 10.1007/s00330-012-2423-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
296 Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res. 2014;74:2731-2741. [PMID: 24626092 DOI: 10.1158/0008-5472.can-13-2044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
297 Hopfner M, Schuppan D, Scherubl H. Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol 2008;14:7021-32. [PMID: 19084910 DOI: 10.3748/wjg.14.7021] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
298 Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 2010;21:269-74. [PMID: 19901014 DOI: 10.1093/annonc/mdp512] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
299 Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:230-242. [PMID: 27239240 DOI: 10.1177/1758834016635888] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
300 Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19:5051-5060. [PMID: 23964138 DOI: 10.3748/wjg.v19.i31.5051] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
301 Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5:221-234. [PMID: 23858331 DOI: 10.1177/1758834013485111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
302 Waterston AM, Cassidy J. Adjuvant treatment strategies for early colon cancer. Drugs 2005;65:1935-47. [PMID: 16162019 DOI: 10.2165/00003495-200565140-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
303 de Cuba EM, de Hingh IH, Sluiter NR, Kwakman R, Coupé VM, Beliën JA, Verwaal VJ, Meijerink WJ, Delis-van Diemen PM, Bonjer HJ, Meijer GA, Te Velde EA. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer. Ann Surg Oncol 2016;23:1601-8. [PMID: 26727921 DOI: 10.1245/s10434-015-5023-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
304 Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-73. [PMID: 18981004 DOI: 10.1158/1078-0432.CCR-08-0260] [Cited by in Crossref: 133] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
305 Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14:135-41. [PMID: 21188500 DOI: 10.1007/s10456-010-9197-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
306 Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol 2016;11:383-400. [PMID: 26706237 DOI: 10.1007/s11523-015-0402-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
307 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 121] [Article Influence: 78.5] [Reference Citation Analysis]
308 Hsu MC, Pan MR, Hung WC. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3. Cells 2019;8:E270. [PMID: 30901976 DOI: 10.3390/cells8030270] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
309 Reinacher-Schick AC, Bechstein WO. [Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology]. Internist (Berl) 2007;48:51-8. [PMID: 17160665 DOI: 10.1007/s00108-006-1770-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
310 Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr 2011;35:86-90. [PMID: 21245693 DOI: 10.1097/RCT.0b013e3181fce2cb] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
311 Wurz GT, Kao CJ, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016;8:4-31. [PMID: 26753003 DOI: 10.1177/1758834015615514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
312 Klauber-Demore N. Are epsins a therapeutic target for tumor angiogenesis? J Clin Invest 2012;122:4341-3. [PMID: 23187137 DOI: 10.1172/JCI66171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
313 Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009;11:987-1002. [PMID: 19794958 DOI: 10.1593/neo.09670] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
314 Thomann S, Longerich T, Bazhin AV, Mier W, Schemmer P, Ryschich E. Selective targeting of liver cancer with the endothelial marker CD146. Oncotarget 2014;5:8614-24. [PMID: 25238265 DOI: 10.18632/oncotarget.2345] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
315 Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415-429. [PMID: 22898649 DOI: 10.1016/j.survophthal.2012.01.007] [Cited by in Crossref: 201] [Cited by in F6Publishing: 166] [Article Influence: 22.3] [Reference Citation Analysis]
316 Yamagishi N, Teshima-Kondo S, Masuda K, Nishida K, Kuwano Y, Dang DT, Dang LH, Nikawa T, Rokutan K. Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. BMC Cancer 2013;13:229. [PMID: 23651517 DOI: 10.1186/1471-2407-13-229] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
317 Park EJ, Baek JH, Choi GS, Park WC, Yu CS, Kang SB, Min BS, Kim JH, Kim HR, Lee BH, Oh JH, Jeong SY, Jung M, Ahn JB, Baik SH. The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. Cancers (Basel) 2020;12:E2306. [PMID: 32824392 DOI: 10.3390/cancers12082306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
318 Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123:3190-3200. [PMID: 23908119 DOI: 10.1172/jci70212] [Cited by in Crossref: 392] [Cited by in F6Publishing: 192] [Article Influence: 49.0] [Reference Citation Analysis]
319 Chen H, Feng J, Zhang Y, Shen A, Chen Y, Lin J, Lin W, Sferra TJ, Peng J. Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1 α /VEGF-A Pathway in Colorectal Cancer. Evid Based Complement Alternat Med 2015;2015:454279. [PMID: 25649293 DOI: 10.1155/2015/454279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
320 Bertero L, Spadi R, Osella-Abate S, Mariani S, Castellano I, Gambella A, Racca P, Morino M, Cassoni P. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. World J Surg Oncol 2020;18:65. [PMID: 32241284 DOI: 10.1186/s12957-020-01844-5] [Reference Citation Analysis]
321 Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:102736. [PMID: 25143961 DOI: 10.1155/2014/102736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
322 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
323 Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010;30:67-78. [PMID: 20140479 DOI: 10.1007/s11239-010-0441-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
324 Liu N, Wu C, Jia R, Cai G, Wang Y, Zhou L, Ji Q, Sui H, Zeng P, Xiao H, Liu H, Huo J, Feng Y, Deng W, Li Q. Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Front Pharmacol 2020;11:478. [PMID: 32372960 DOI: 10.3389/fphar.2020.00478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
325 Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, Lund JL. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. Oncologist 2020;25:46-54. [PMID: 31611329 DOI: 10.1634/theoncologist.2019-0338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Mancuso MR, Davis R, Norberg SM, O’Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610-2621. [PMID: 17016557 DOI: 10.1172/jci24612] [Cited by in Crossref: 578] [Cited by in F6Publishing: 269] [Article Influence: 41.3] [Reference Citation Analysis]
327 Okugawa Y, Toiyama Y, Goel A. An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn. 2014;14:999-1021. [PMID: 25163355 DOI: 10.1586/14737159.2014.946907] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
328 Jha PK, Vankalakunti M, Siddini V, Bonu R, Prakash GK, Babu K, Ballal HS. Sunitinib induced nephrotic syndrome and thrombotic microangiopathy. Indian J Nephrol 2013;23:67-70. [PMID: 23580811 DOI: 10.4103/0971-4065.107215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
329 Morris ZS, Harari PM. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 2014;32:2886-93. [PMID: 25113770 DOI: 10.1200/JCO.2014.55.1366] [Cited by in Crossref: 63] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
330 Kim SY, S Hong Y, K Shim E, Kong SY, Shin A, Baek JY, Jung KH. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. Br J Cancer. 2013;109:1420-1427. [PMID: 23963147 DOI: 10.1038/bjc.2013.479] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
331 Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, Yuan J, Chen R, Li Y, Ge Z, Ji J, Zhang L, Wang J, Li Z, Lai Y, Hu Y, Li Y, Li Y, Gao J, Chen L, Xu J, Zhang C, Jung SY, Choi JM, Jain A, Liu M, Song L, Liu W, Guo G, Gong T, Huang Y, Qiu Y, Huang W, Shi T, Zhu W, Wang Y, He F, Shen L, Qin J. A proteomic landscape of diffuse-type gastric cancer. Nat Commun 2018;9:1012. [PMID: 29520031 DOI: 10.1038/s41467-018-03121-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 23.0] [Reference Citation Analysis]
332 Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y. Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells. Oncotarget 2018;9:17620-30. [PMID: 29707135 DOI: 10.18632/oncotarget.24811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
333 Ow TJ, Sandulache VC, Skinner HD, Myers JN. Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. Cancer 2013;119:3914-28. [PMID: 24037788 DOI: 10.1002/cncr.28304] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
334 Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ, Burris HA 3rd. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61. [PMID: 21147873 DOI: 10.1634/theoncologist.2010-0095] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
335 Broséus J, Mourah S, Ramstein G, Bernard S, Mounier N, Cuccuini W, Gaulard P, Gisselbrecht C, Brière J, Houlgatte R, Thieblemont C. VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. Oncotarget 2017;8:90808-24. [PMID: 29207605 DOI: 10.18632/oncotarget.19385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
336 Mercer RW, Tyler MA, Ulasov IV, Lesniak MS. Targeted therapies for malignant glioma: progress and potential. BioDrugs 2009;23:25-35. [PMID: 19344189 DOI: 10.2165/00063030-200923010-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
337 Bermúdez M, Aguilar-Medina M, Lizárraga-Verdugo E, Avendaño-Félix M, Silva-Benítez E, López-Camarillo C, Ramos-Payán R. LncRNAs as Regulators of Autophagy and Drug Resistance in Colorectal Cancer. Front Oncol 2019;9:1008. [PMID: 31632922 DOI: 10.3389/fonc.2019.01008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
338 Liu Y, Luan L, Wang X. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. Onco Targets Ther 2015;8:1061-8. [PMID: 25999741 DOI: 10.2147/OTT.S81442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
339 Kanagawa N, Yanagawa T, Nakagawa T, Okada N, Nakagawa S. Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther 2013;20:57-64. [PMID: 23175243 DOI: 10.1038/cgt.2012.85] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
340 de la Torre P, Pérez-Lorenzo MJ, Alcázar-Garrido Á, Flores AI. Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. Molecules 2020;25:E715. [PMID: 32046010 DOI: 10.3390/molecules25030715] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
341 Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs. 2009;27:184-187. [PMID: 18665327 DOI: 10.1007/s10637-008-9162-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
342 Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-7. [PMID: 17179168 DOI: 10.1136/bjo.2006.107912] [Cited by in Crossref: 150] [Cited by in F6Publishing: 117] [Article Influence: 10.0] [Reference Citation Analysis]
343 Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2017;79:17-27. [PMID: 27872953 DOI: 10.1007/s00280-016-3189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
344 Giessen C, Laubender RP, Fischer von Weikersthal L, Schalhorn A, Modest DP, Stintzing S, Haas M, Mansmann UR, Heinemann V. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci. 2013;104:718-724. [PMID: 23480146 DOI: 10.1111/cas.12148] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
345 Chen ZI, Ai DI. Cardiotoxicity associated with targeted cancer therapies. Mol Clin Oncol 2016;4:675-81. [PMID: 27123262 DOI: 10.3892/mco.2016.800] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
346 Angerilli V, Galuppini F, Businello G, Dal Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V, Lonardi S, Loupakis F, Fassan M. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines 2021;9:318. [PMID: 33801049 DOI: 10.3390/biomedicines9030318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
347 Holtz DO, Krafty RT, Mohamed-Hadley A, Zhang L, Alagkiozidis I, Leiby B, Guo W, Gimotty PA, Coukos G. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med 2008;6:2. [PMID: 18182107 DOI: 10.1186/1479-5876-6-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
348 Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3395-402. [PMID: 17545548 DOI: 10.1158/1078-0432.CCR-06-2441] [Cited by in Crossref: 217] [Cited by in F6Publishing: 112] [Article Influence: 15.5] [Reference Citation Analysis]
349 Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 2016;126:1885-96. [PMID: 27064283 DOI: 10.1172/JCI85086] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 11.4] [Reference Citation Analysis]
350 Chen YC, Ou MC, Fang CW, Lee TH, Tzeng SL. High Glucose Concentrations Negatively Regulate the IGF1R/Src/ERK Axis through the MicroRNA-9 in Colorectal Cancer. Cells 2019;8:E326. [PMID: 30965609 DOI: 10.3390/cells8040326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
351 van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32:457-465. [PMID: 25899064 DOI: 10.1007/s10585-015-9719-0] [Cited by in Crossref: 191] [Cited by in F6Publishing: 162] [Article Influence: 31.8] [Reference Citation Analysis]
352 Ladha H, Pawar T, Gilbert MR, Mandel J, O-Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong TS. Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol 2015;124:501-6. [PMID: 26298437 DOI: 10.1007/s11060-015-1868-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
353 Qiao G, Qin J, Kunda N, Calata JF, Mahmud DL, Gann P, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV. LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer Res 2017;77:1880-91. [PMID: 28249900 DOI: 10.1158/0008-5472.CAN-16-1655] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
354 Ray MR, Jablons D, He B. Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med 2010;4:631-45. [PMID: 20923341 DOI: 10.1586/ers.10.64] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
355 Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: current developments. World J Gastroenterol 2014;20:10425-31. [PMID: 25132758 DOI: 10.3748/wjg.v20.i30.10425] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
356 Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 2012;107:351-8. [PMID: 22076449 DOI: 10.1007/s11060-011-0748-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
357 Di Salvatore M, Orlandi A, Bagalà C, Quirino M, Cassano A, Astone A, Barone C. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011;44:139-46. [PMID: 21401755 DOI: 10.1111/j.1365-2184.2011.00745.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
358 DeStefanis RA, Kratz JD, Emmerich PB, Deming DA. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep 2019;15:61-9. [PMID: 31130830 DOI: 10.1007/s11888-019-00430-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
359 Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med 2016;14:119. [PMID: 27149858 DOI: 10.1186/s12967-016-0872-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
360 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 12.7] [Reference Citation Analysis]
361 Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, DE Placido S, Tortora G. Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. Exp Ther Med 2011;2:449-55. [PMID: 22977524 DOI: 10.3892/etm.2011.218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
362 Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011;105:44-52. [PMID: 21629245 DOI: 10.1038/bjc.2011.182] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
363 Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci U S A 2015;112:14676-81. [PMID: 26554010 DOI: 10.1073/pnas.1512570112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
364 Eisen T, Shparyk Y, Macleod N, Jones R, Wallenstein G, Temple G, Khder Y, Dallinger C, Studeny M, Loembe AB, Bondarenko I. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs 2013;31:1283-93. [PMID: 23625328 DOI: 10.1007/s10637-013-9962-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
365 Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol. 2012;23:2812-2820. [PMID: 22767582 DOI: 10.1093/annonc/mds134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
366 Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;69:1534-43. [PMID: 17889445 DOI: 10.1016/j.ijrobp.2007.07.2350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
367 Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 2006;8:889-95. [PMID: 17132220 DOI: 10.1593/neo.06535] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
368 Park DJ, Thomas NJ, Yoon C, Yoon SS. Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer. 2015;18:33-42. [PMID: 24993497 DOI: 10.1007/s10120-014-0397-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
369 Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol 2015;11:909-22. [PMID: 25760973 DOI: 10.2217/fon.14.276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
370 Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clin Cancer Res 2017;23:5489-501. [PMID: 28559461 DOI: 10.1158/1078-0432.CCR-16-3216] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
371 Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76:925-32. [PMID: 26370544 DOI: 10.1007/s00280-015-2850-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
372 Faes S, Uldry E, Planche A, Santoro T, Pythoud C, Demartines N, Dormond O. Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies. Oncotarget 2016;7:86026-38. [PMID: 27852069 DOI: 10.18632/oncotarget.13323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
373 Huy TL, Bui MH, Dinh TC, Xuyen HTH. Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. Open Access Maced J Med Sci 2019;7:4244-9. [PMID: 32215071 DOI: 10.3889/oamjms.2019.368] [Reference Citation Analysis]
374 Iemoto T, Nishiumi S, Kobayashi T, Fujigaki S, Hamaguchi T, Kato K, Shoji H, Matsumura Y, Honda K, Yoshida M. Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncol Lett 2019;17:831-42. [PMID: 30655836 DOI: 10.3892/ol.2018.9731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
375 Medinger M, Passweg J. Angiogenesis in myeloproliferative neoplasms, new markers and future directions. Memo 2014;7:206-10. [PMID: 25544863 DOI: 10.1007/s12254-014-0142-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
376 Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World J Gastroenterol. 2015;21:11767-11776. [PMID: 26557001 DOI: 10.3748/wjg.v21.i41.11767] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 80] [Article Influence: 20.8] [Reference Citation Analysis]
377 Campanella C, Mottolese M, Cianciulli A, Torsello A, Merola R, Sperduti I, Melucci E, Conti S, Diodoro MG, Zeuli M, Paoletti G, Cognetti F, Garufi C. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. J Transl Med 2010;8:36. [PMID: 20398370 DOI: 10.1186/1479-5876-8-36] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
378 Kim ST, Chang WJ, Jin L, Sung JS, Choi YJ, Kim YH. Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer? Cancer Res Treat 2015;47:796-803. [PMID: 25687873 DOI: 10.4143/crt.2014.106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
379 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med. 2015;4:1836-1843. [PMID: 26471348 DOI: 10.1002/cam4.548] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
380 Luo Y, Wang L, Chen C, Chen D, Huang M, Huang Y, Peng J, Lan P, Cui J, Cai S. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastases. J Gastrointest Surg. 2010;14:1974-1980. [PMID: 20676791 DOI: 10.1007/s11605.010-1284-x] [Reference Citation Analysis]
381 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
382 Yoshimoto T, Yoshikawa K, Higashijima J, Miyatani T, Tokunaga T, Nishi M, Takasu C, Kashihara H, Takehara Y, Shimada M. Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab. Ann Gastroenterol Surg 2020;4:151-5. [PMID: 32258980 DOI: 10.1002/ags3.12312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
383 Lu CY, Huang CW, Wu IC, Tsai HL, Ma CJ, Yeh YS, Chang SF, Huang ML, Wang JY. Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting. Transl Oncol 2015;8:474-9. [PMID: 26692528 DOI: 10.1016/j.tranon.2015.11.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
384 Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol 2017;70:2552-65. [PMID: 29145955 DOI: 10.1016/j.jacc.2017.09.1095] [Cited by in Crossref: 110] [Cited by in F6Publishing: 77] [Article Influence: 27.5] [Reference Citation Analysis]
385 Yin L, Li J, Ma D, Li D, Sun Y. Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies. Oncol Lett 2020;19:3558-66. [PMID: 32269630 DOI: 10.3892/ol.2020.11450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
386 Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D. Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Hum Genome Var 2015;2:15009. [PMID: 27081524 DOI: 10.1038/hgv.2015.9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
387 Touil YS, Fellous A, Scherman D, Chabot GG. Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization. Nutr Cancer 2009;61:310-21. [PMID: 19373604 DOI: 10.1080/01635580802521346] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
388 Tayama M, Furuhata T, Inafuku Y, Okita K, Nishidate T, Mizuguchi T, Kimura Y, Hirata K. Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World J Gastroenterol. 2011;17:4867-4874. [PMID: 22171127 DOI: 10.3748/wjg.v17.i44.4867] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
389 Tian L, Bae YH. Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf B Biointerfaces 2012;99:116-26. [PMID: 22078927 DOI: 10.1016/j.colsurfb.2011.10.039] [Cited by in Crossref: 89] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
390 Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18:e84-e96. [PMID: 21505593 DOI: 10.3747/co.v18i2.663] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
391 Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med 2020;9:E675. [PMID: 32138216 DOI: 10.3390/jcm9030675] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
392 Luo M, Wicha MS. Targeting Cancer Stem Cell Redox Metabolism to Enhance Therapy Responses. Semin Radiat Oncol. 2019;29:42-54. [PMID: 30573183 DOI: 10.1016/j.semradonc.2018.10.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
393 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
394 Yeh YS, Tsai HL, Huang CW, Wang JH, Lin YW, Tang HC, Sung YC, Wu CC, Lu CY, Wang JY. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials 2016;17:46. [PMID: 26811156 DOI: 10.1186/s13063-016-1153-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
395 Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91. [PMID: 17537235 DOI: 10.1186/1471-2407-7-91] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
396 Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 2006;169:2054-65. [PMID: 17148668 DOI: 10.2353/ajpath.2006.060653] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 5.6] [Reference Citation Analysis]
397 Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, Zheng C, Zuo Y. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. [PMID: 20923544 DOI: 10.1186/1471-2407-10-529] [Cited by in Crossref: 136] [Cited by in F6Publishing: 132] [Article Influence: 12.4] [Reference Citation Analysis]
398 Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97-119. [PMID: 28085225 DOI: 10.1002/1878-0261.12018] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 17.5] [Reference Citation Analysis]
399 Helmberger T, Hoffmann RT, Jakobs T, Leibecke T, Lubienski A, Reiser M. [Liver tumor ablation]. Radiologe. 2005;45:55-62. [PMID: 15609015 DOI: 10.1007/s00117-004-1149-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
400 Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18. [PMID: 20010945 DOI: 10.1038/sj.bjc.6605483] [Cited by in Crossref: 162] [Cited by in F6Publishing: 134] [Article Influence: 13.5] [Reference Citation Analysis]
401 Tokunaga Y, Kawasaki T, Sasaki H, Matsueda S, Saito T. Hepatic metastasis from bile duct cancer of the ampulla is effectively controlled by multidisciplinary treatment including S-1, gemcitabine and bevacizumab: A case report. Oncol Lett 2010;1:481-4. [PMID: 22966328 DOI: 10.3892/ol_00000084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
402 Dekker E, van Gulik T. Colorectal cancer: what the clinician wants to know. Cancer Imaging 2005;5 Spec No A:S127-32. [PMID: 16361128 DOI: 10.1102/1470-7330.2005.0036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
403 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
404 Biel NM, Siemann DW. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett 2016;380:525-33. [PMID: 25312939 DOI: 10.1016/j.canlet.2014.09.035] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
405 Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 2015;6:8792. [PMID: 26635184 DOI: 10.1038/ncomms9792] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
406 Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 2011;27:219-24. [PMID: 21574814 DOI: 10.1089/jop.2010.0158] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
407 Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70:65-74. [PMID: 22623210 DOI: 10.1007/s00280-012-1880-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
408 Nanashima A, Takeshita H, Abo T, Tou K, Tanaka K, Fukuda D, Kunizaki M, Hidaka S, Sawai T. Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis. J Gastrointest Oncol 2013;4:164-72. [PMID: 23730512 DOI: 10.3978/j.issn.2078-6891.2013.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
409 Salmon AH, Neal CR, Bates DO, Harper SJ. Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli. J Physiol 2006;570:141-56. [PMID: 16239266 DOI: 10.1113/jphysiol.2005.099184] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
410 Ribatti D. The inefficacy of antiangiogenic therapies. J Angiogenes Res 2010;2:27. [PMID: 21143947 DOI: 10.1186/2040-2384-2-27] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
411 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
412 Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol. 2011;3:1-9. [PMID: 21267397 DOI: 10.4251/wjgo.v3.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
413 Baker LCJ, Boult JKR, Thomas M, Koehler A, Nayak T, Tessier J, Ooi CH, Birzele F, Belousov A, Zajac M, Horn C, LeFave C, Robinson SP. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. Br J Cancer 2016;115:691-702. [PMID: 27529514 DOI: 10.1038/bjc.2016.236] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
414 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
415 Desautels D, Harlos C, Czaykowski P. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog 2014;13:13. [PMID: 25525412 DOI: 10.4103/1477-3163.145609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
416 Ahn HJ, Oh HS, Ahn Y, Lee SJ, Kim HJ, Kim MH, Eom DW, Kwak JY, Han MS, Song JS. Prognostic Implications of Primary Tumor Resection in Stage IVB Colorectal Cancer in Elderly Patients. Ann Coloproctol 2014;30:175-81. [PMID: 25210686 DOI: 10.3393/ac.2014.30.4.175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
417 Newman JR, Helman EE, Safavy S, Zhang W, Rosenthal EL. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett 2009;274:313-8. [PMID: 18990485 DOI: 10.1016/j.canlet.2008.09.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
418 Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Lett 2016;381:217-36. [PMID: 26742462 DOI: 10.1016/j.canlet.2015.11.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
419 Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, Li S, Lian B, Gu K, Tao M, Song X, Lin T, Ren X, Qin S, Guo J. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 2013;21:1456-63. [PMID: 23670576 DOI: 10.1038/mt.2013.79] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
420 Enninga EA, Nevala WK, Holtan SG, Markovic SN. Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. Front Immunol 2015;6:424. [PMID: 26379664 DOI: 10.3389/fimmu.2015.00424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
421 Ozcelik M, Odabas H, Ercelep O, Yuksel S, Mert AG, Aydin D, Surmeli H, Isik D, Isik S, Oyman A, Oven Ustaalioglu BB, Aliustaoglu M, Gumus M. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clin Transl Oncol 2016;18:617-24. [PMID: 26459249 DOI: 10.1007/s12094-015-1408-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
422 Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2011;107:741-7. [PMID: 21355978 DOI: 10.1111/j.1464-410X.2010.09626.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
423 Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021;13:295-304. [PMID: 33889280 DOI: 10.4251/wjgo.v13.i4.295] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83. [PMID: 19773375 DOI: 10.1158/1078-0432.CCR-09-0717] [Cited by in Crossref: 68] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
425 Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-84. [PMID: 21275455 DOI: 10.1007/BF03256395] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
426 d'Onofrio A, Gandolfi A, Rocca A. The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. Cell Prolif 2009;42:317-29. [PMID: 19438898 DOI: 10.1111/j.1365-2184.2009.00595.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
427 Cho T, Shiozawa E, Urushibara F, Arai N, Funaki T, Takehara Y, Tazawa S, Misawa M, Homma M, Norose T, Omatsu M, Miyachi H, Yamochi T, Kunimura T, Tate G, Ishida F, Kudo SE, Takimoto M. The role of microvessel density, lymph node metastasis, and tumor size as prognostic factors of distant metastasis in colorectal cancer. Oncol Lett. 2017;13:4327-4333. [PMID: 28599434 DOI: 10.3892/ol.2017.5959] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
428 Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. Oncologist 2020;25:e469-76. [PMID: 32162797 DOI: 10.1634/theoncologist.2019-0541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
429 Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. [PMID: 25376790 DOI: 10.1186/1471-2407-14-820] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 14.1] [Reference Citation Analysis]
430 Chen D, Zhang X, Gao G, Shen L, Xie J, Qian X, Wang H. Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis. World J Surg Oncol 2018;16:200. [PMID: 30296945 DOI: 10.1186/s12957-018-1502-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
431 Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia 2011;13:419-27. [PMID: 21532882 DOI: 10.1593/neo.101508] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
432 Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 2009;15:3189-95. [PMID: 19383814 DOI: 10.1158/1078-0432.CCR-08-2999] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
433 Legué LM, van Erning FN, Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. Target Oncol 2019;14:699-705. [PMID: 31625001 DOI: 10.1007/s11523-019-00681-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
434 Sefah K, Meng L, Lopez-Colon D, Jimenez E, Liu C, Tan W. DNA aptamers as molecular probes for colorectal cancer study. PLoS One. 2010;5:e14269. [PMID: 21170319 DOI: 10.1371/journal.pone.0014269] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 7.1] [Reference Citation Analysis]
435 Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1:14-25. [PMID: 25806151 DOI: 10.3978/j.issn.2218-6751.2011.11.02] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
436 Pimple S, Manjappa AS, Ukawala M, Murthy RS. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnol 2012;3:25-36. [PMID: 26069494 DOI: 10.1007/s12645-012-0027-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
437 Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014;20:4210-4217. [PMID: 25125258 DOI: 10.1158/1078-0432.ccr-14-0521] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
438 Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007;25:165-72. [PMID: 16983506 DOI: 10.1007/s10637-006-9011-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
439 Flores AM, Ye J, Jarr KU, Hosseini-Nassab N, Smith BR, Leeper NJ. Nanoparticle Therapy for Vascular Diseases. Arterioscler Thromb Vasc Biol 2019;39:635-46. [PMID: 30786744 DOI: 10.1161/ATVBAHA.118.311569] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 33.0] [Reference Citation Analysis]
440 Sherman JH, Aregawi DG, Lai A, Fathallah-Shaykh HM, Bierman PJ, Linsky K, Larner JM, Newman SA, Schiff D. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009;73:1924-6. [PMID: 19949039 DOI: 10.1212/WNL.0b013e3181c3fd00] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
441 Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-16. [PMID: 20940184 DOI: 10.1200/jco.2010.30.0855] [Cited by in Crossref: 415] [Cited by in F6Publishing: 178] [Article Influence: 37.7] [Reference Citation Analysis]
442 Jimeno J, Aracil M, Tercero JC. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med 2006;4:3. [PMID: 16401350 DOI: 10.1186/1479-5876-4-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
443 Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14:13-20. [PMID: 17576459 DOI: 10.3747/co.2007.96] [Cited by in Crossref: 91] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
444 Ronnekleiv-Kelly SM, Kennedy GD. Management of stage IV rectal cancer: palliative options. World J Gastroenterol. 2011;17:835-847. [PMID: 21412493 DOI: 10.3748/wjg.v17.i7.835] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
445 Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther. 2008;7:79-89. [PMID: 18202011 DOI: 10.1158/1535-7163.mct-07-0584] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
446 Yu HK, Lee HJ, Yun SJ, Lee SJ, Langley RR, Yoon Y, Yi LS, Bae DS, Kim JS, Kim SJ. Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. Transl Oncol 2014;7:368-76. [PMID: 25180060 DOI: 10.1016/j.tranon.2014.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
447 Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18. [PMID: 27009393 DOI: 10.1038/nrc.2016.25] [Cited by in Crossref: 671] [Cited by in F6Publishing: 574] [Article Influence: 134.2] [Reference Citation Analysis]
448 Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol 2009;5:703-12. [PMID: 19519209 DOI: 10.2217/fon.09.33] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
449 Dong G, Guo X, Fu X, Wan S, Zhou F, Myers RE, Bao G, Burkart A, Yang H, Xing J. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. Cancer Sci 2012;103:561-8. [PMID: 22182247 DOI: 10.1111/j.1349-7006.2011.02194.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
450 Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 2011;17:7634-44. [PMID: 22038997 DOI: 10.1158/1078-0432.CCR-11-1677] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
451 Mahmood RD, Shaw D, Descamps T, Zhou C, Morgan RD, Mullamitha S, Saunders M, Mescallado N, Backen A, Morris K, Little RA, Cheung S, Watson Y, O'Connor JPB, Jackson A, Parker GJM, Dive C, Jayson GC. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. BMC Cancer 2021;21:354. [PMID: 33794823 DOI: 10.1186/s12885-021-08097-9] [Reference Citation Analysis]
452 Li C. A targeted approach to cancer imaging and therapy. Nat Mater 2014;13:110-5. [PMID: 24452345 DOI: 10.1038/nmat3877] [Cited by in Crossref: 197] [Cited by in F6Publishing: 163] [Article Influence: 28.1] [Reference Citation Analysis]
453 Kanda A, Ishida S. (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy. J Diabetes Investig 2019;10:6-17. [PMID: 29575757 DOI: 10.1111/jdi.12842] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
454 Ch'ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015;7:2029-40. [PMID: 26261692 DOI: 10.4254/wjh.v7.i16.2029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
455 Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 2007;97:391-7. [PMID: 17609662 DOI: 10.1038/sj.bjc.6603875] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
456 Subauste MC, Kupriyanova TA, Conn EM, Ardi VC, Quigley JP, Deryugina EI. Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems. Clin Exp Metastasis 2009;26:1033-47. [PMID: 19842048 DOI: 10.1007/s10585-009-9293-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
457 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
458 Chilà R, Hall G T, Abbadessa G, Broggini M, Damia G. Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models. Transl Oncol 2017;10:153-7. [PMID: 28161661 DOI: 10.1016/j.tranon.2016.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
459 Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig. 2013;33:779-788. [PMID: 23979925 DOI: 10.1007/s40261-013-0125-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
460 Zulato E, Bergamo F, De Paoli A, Griguolo G, Esposito G, De Salvo GL, Mescoli C, Rugge M, Nardin M, Di Grazia L, Lonardi S, Indraccolo S, Zagonel V. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer 2014;111:25-32. [PMID: 24892446 DOI: 10.1038/bjc.2014.274] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
461 Zhou M, Yu P, Qu X, Liu Y, Zhang J. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One 2013;8:e81858. [PMID: 24324725 DOI: 10.1371/journal.pone.0081858] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
462 Lee ST, Tebbutt N, Gan HK, Liu Z, Sachinidis J, Pathmaraj K, Scott AM. Evaluation of 18F-FMISO PET and 18F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy. Front Oncol 2021;11:606210. [PMID: 33816239 DOI: 10.3389/fonc.2021.606210] [Reference Citation Analysis]
463 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 100] [Article Influence: 10.7] [Reference Citation Analysis]
464 Ghafouri-Fard S, Abak A, Tondro Anamag F, Shoorei H, Fattahi F, Javadinia SA, Basiri A, Taheri M. 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Front Oncol 2021;11:658636. [PMID: 33954114 DOI: 10.3389/fonc.2021.658636] [Reference Citation Analysis]
465 Veenstra CM, Krauss JC. Emerging Systemic Therapies for Colorectal Cancer. Clin Colon Rectal Surg 2018;31:179-91. [PMID: 29720904 DOI: 10.1055/s-0037-1602238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
466 Cho BC, Kim JH, Soo RA, Yang CH. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J 2010;51:1-8. [PMID: 20046507 DOI: 10.3349/ymj.2010.51.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
467 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21. [PMID: 21364524 DOI: 10.1038/nrclinonc.2011.21] [Cited by in Crossref: 474] [Cited by in F6Publishing: 406] [Article Influence: 47.4] [Reference Citation Analysis]
468 Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Faragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol 2015;54:487-92. [PMID: 25549537 DOI: 10.3109/0284186X.2014.990158] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
469 Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. Oncologist 2017;22:694-9. [PMID: 28592621 DOI: 10.1634/theoncologist.2016-0455] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
470 Torres OJ, Marques MC, Santos FN, Farias IC, Coutinho AK, Oliveira CV, Kalil AN, Mello CA, Kruger JA, Fernandes GD, Quireze C Jr, Murad AM, Silva MJ, Zurstrassen CE, Freitas HC, Cruz MR, Weschenfelder R, Linhares MM, Castro LD, Vollmer C, Dixon E, Ribeiro HS, Coimbra FJ. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arq Bras Cir Dig 2016;29:173-9. [PMID: 27759781 DOI: 10.1590/0102-6720201600030011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
471 Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2010;2:19-30. [PMID: 21160813 DOI: 10.4251/wjgo.v2.i1.19] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
472 O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007;69:S64-6. [PMID: 17848299 DOI: 10.1016/j.ijrobp.2007.04.093] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
473 Liang HL, Hu AP, Li SL, Liu JY. Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Med Oncol 2014;31:976. [PMID: 24793617 DOI: 10.1007/s12032-014-0976-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
474 Okada S, Yamazaki S, Kaiga T, Funada T, Kochi M, Takayama T. Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy. World J Surg Oncol 2017;15:162. [PMID: 28836976 DOI: 10.1186/s12957-017-1226-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
475 Zanwar S, Ostwal V, Gupta S, Sirohi B, Toshniwal A, Shetty N, Banavali S. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med 2016;4:74. [PMID: 27004221 DOI: 10.3978/j.issn.2305-5839.2016.02.05] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
476 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
477 Eichhorn ME, Kleespies A, Angele MK, Jauch KW, Bruns CJ. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007;392:371-9. [PMID: 17458577 DOI: 10.1007/s00423-007-0150-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
478 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013;15:106-15. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
479 Falcón BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175:2159-70. [PMID: 19815705 DOI: 10.2353/ajpath.2009.090391] [Cited by in Crossref: 156] [Cited by in F6Publishing: 130] [Article Influence: 13.0] [Reference Citation Analysis]
480 Yasui H, Sato K, Takeyama Y, Kato T, Hashimoto H, Fukui Y, Yoshihisa N, Maeda M, Gonda H, Suzuki R. Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy. Case Rep Oncol 2014;7:583-90. [PMID: 25298764 DOI: 10.1159/000366268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
481 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
482 Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy Pract 2017;2:2381468317729650. [PMID: 30288431 DOI: 10.1177/2381468317729650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
483 Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med 2014;7:137-44. [PMID: 25045279 DOI: 10.2147/PGPM.S47582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
484 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
485 Wang Y, Dong J, Quan Q, Liu S, Chen X, Cai X, Qiu H, Zhang B, Guo G. Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients. Front Oncol 2020;10:581051. [PMID: 33585196 DOI: 10.3389/fonc.2020.581051] [Reference Citation Analysis]
486 Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Casanova M, Merks JH, Massimino M, Grill J, Daw NC, Navid F, Jin J, Allison DE. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 2016;81:148-60. [PMID: 26345283 DOI: 10.1111/bcp.12778] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
487 Kinoshita O, Kishimoto M, Murayama Y, Kuriu Y, Nakanishi M, Sakakura C, Otsuji E, Yanagisawa A. The number of metastatic lymph nodes exhibiting poorly differentiated clusters predicts survival in patients with pStage III colorectal cancer. Int J Colorectal Dis 2016;31:283-90. [PMID: 26412250 DOI: 10.1007/s00384-015-2393-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
488 Cheng JW, Cheng SW, Lu GC, Wei RL. Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis. PLoS One 2012;7:e41325. [PMID: 22829940 DOI: 10.1371/journal.pone.0041325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
489 Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 2012;18:4820-9. [PMID: 22767667 DOI: 10.1158/1078-0432.CCR-12-0098] [Cited by in Crossref: 121] [Cited by in F6Publishing: 86] [Article Influence: 13.4] [Reference Citation Analysis]
490 George TJ, Ivey AM, Ali A, Lee JH, Wang Y, Daily KC, Ramnaraign BH, Tan SA, Terracina KP, Read TE, Dang LH, Iqbal A. Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. Oncologist 2021;26:362-e724. [PMID: 33512054 DOI: 10.1002/onco.13689] [Reference Citation Analysis]
491 Landre T, Maillard E, Taleb C, Ghebriou D, Guetz GD, Zelek L, Aparicio T. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis 2018;33:1125-30. [PMID: 29680896 DOI: 10.1007/s00384-018-3053-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
492 Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs 2008;10:177-92. [PMID: 18454570 DOI: 10.2165/00148581-200810030-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
493 Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med 2016;8:39-57. [PMID: 26666269 DOI: 10.15252/emmm.201505505] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 17.2] [Reference Citation Analysis]
494 Honma K, Takemasa I, Matoba R, Yamamoto Y, Takeshita F, Mori M, Monden M, Matsubara K, Ochiya T. Screening of potential molecular targets for colorectal cancer therapy. Int J Gen Med 2009;2:243-57. [PMID: 20360909 DOI: 10.2147/ijgm.s5158] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
495 Shi M, Ma T, Xi W, Jiang J, Wu J, Zhou C, Yang C, Zhu Z, Zhang J. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials 2020;21:249. [PMID: 32143730 DOI: 10.1186/s13063-020-4194-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
496 Ghazi NG, Kirk TQ, Knape RM, Tiedeman JS, Conway BP. Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration? Clin Ophthalmol 2010;4:307-14. [PMID: 20463798 DOI: 10.2147/opth.s8598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
497 Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16:1325-1332. [PMID: 21807768 DOI: 10.1634/theoncologist.2010-0002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
498 Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecol Oncol 2016;141:80-5. [PMID: 26748214 DOI: 10.1016/j.ygyno.2015.12.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
499 Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. J Oncol Pract 2012;8:190-5. [PMID: 22942815 DOI: 10.1200/JOP.2011.000337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
500 Lecarpentier E, Ouaffi L, Mir O, Berveiller P, Maurel M, Pujade-lauraine E, Bouillot JL, Veyrie N. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Invest New Drugs 2011;29:1500-3. [DOI: 10.1007/s10637-010-9505-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
501 Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87:262-271. [PMID: 20400620 DOI: 10.1093/cvr/cvq105] [Cited by in Crossref: 264] [Cited by in F6Publishing: 215] [Article Influence: 24.0] [Reference Citation Analysis]
502 Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol 2014;20:3751-61. [PMID: 24744571 DOI: 10.3748/wjg.v20.i14.3751] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 82] [Article Influence: 16.7] [Reference Citation Analysis]
503 Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Augustin HG, Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207:491-503. [PMID: 20194633 DOI: 10.1084/jem.20091846] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 12.6] [Reference Citation Analysis]
504 Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies. Oncotarget 2017;8:9174-88. [PMID: 27999187 DOI: 10.18632/oncotarget.13942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
505 Osoegawa A, Kometani T, Fukuyama S, Hirai F, Seto T, Sugio K, Ichinose Y. Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma. Ann Thorac Cardiovasc Surg 2016;22:6-11. [PMID: 26289631 DOI: 10.5761/atcs.oa.14-00345] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
506 Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol 2013;7:259-82. [PMID: 23522958 DOI: 10.1016/j.molonc.2013.02.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 9.5] [Reference Citation Analysis]
507 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
508 Keefe DM, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 2007;15:483-90. [PMID: 17103195 DOI: 10.1007/s00520-006-0181-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
509 Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005;28:417-33. [PMID: 15853443 DOI: 10.2165/00002018-200528050-00005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
510 Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Invest New Drugs. 2016;34:119-128. [PMID: 26643663 DOI: 10.1007/s10637-015-0309-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
511 Pang RW, Poon RT. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag. 2006;2:97-108. [PMID: 17319453 DOI: 10.2147/vhrm.2006.2.2.97] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
512 Siegal T. Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol 2013;15:656-69. [PMID: 23502426 DOI: 10.1093/neuonc/not016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
513 Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14:236-243. [PMID: 23333117 DOI: 10.1016/s1470-2045(12)70567-3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
514 Caporarello N, Lupo G, Olivieri M, Cristaldi M, Cambria MT, Salmeri M, Anfuso CD. Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review). Mol Med Rep 2017;16:4393-402. [PMID: 28791360 DOI: 10.3892/mmr.2017.7179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
515 Folprecht G, Bechstein WO. [Neoadjuvant therapy concepts for liver metastases]. Chirurg. 2011;82:989-994. [PMID: 22033894 DOI: 10.1007/s00104-011-2131-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
516 Chen QY, Liu Y, Cai W, Luesch H. Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity. J Med Chem 2014;57:3011-29. [PMID: 24660812 DOI: 10.1021/jm4019965] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
517 Shangguan W, Fan C, Chen X, Lu R, Liu Y, Li Y, Shang Y, Yin D, Zhang S, Huang Q, Li X, Meng W, Xu H, Zhou Z, Hu J, Mo X. Endothelium originated from colorectal cancer stem cells constitute cancer blood vessels. Cancer Sci 2017;108:1357-67. [PMID: 28421697 DOI: 10.1111/cas.13262] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
518 Eswarappa SM, Fox PL. Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis. Cancer Res 2015;75:2765-9. [PMID: 26122849 DOI: 10.1158/0008-5472.CAN-14-3805] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
519 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
520 Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2019;83:551-9. [PMID: 30603797 DOI: 10.1007/s00280-018-3761-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:301-319. [PMID: 23118806 DOI: 10.1177/1758834012454464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
522 Zhao XC, Dou GR, Wang L, Liang L, Tian DM, Cao XL, Qin HY, Wang CM, Zhang P, Han H. Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells. Neoplasia 2013;15:815-25. [PMID: 23814493 DOI: 10.1593/neo.13550] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
523 Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol 2016;78:341-51. [PMID: 27329360 DOI: 10.1007/s00280-016-3079-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
524 Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers (Basel). 2019;11. [PMID: 30691222 DOI: 10.3390/cancers11020147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
525 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Reference Citation Analysis]
526 Nienhüser H, Schmidt T. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. Int J Mol Sci 2017;19:E43. [PMID: 29295534 DOI: 10.3390/ijms19010043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
527 Yu C, Zhang Y. Development and validation of a prognostic nomogram for early-onset colon cancer. Biosci Rep 2019;39:BSR20181781. [PMID: 31142625 DOI: 10.1042/BSR20181781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
528 Rivadeneira DB, Delgoffe GM. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res 2018;24:2473-81. [PMID: 29386217 DOI: 10.1158/1078-0432.CCR-17-0894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
529 Miwata K, Okamoto H, Nakashima T, Ihara D, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Shibata A, Ito T, Okuda T, Hattori N. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice. Mol Ther Nucleic Acids 2018;12:698-706. [PMID: 30092405 DOI: 10.1016/j.omtn.2018.07.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
530 Yoshida J, Wicks RT, Zambrano AI, Tyler BM, Javaherian K, Grossman R, Daoud YJ, Gehlbach P, Brem H, Stark WJ. Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis. J Ophthalmol 2015;2015:137136. [PMID: 26491546 DOI: 10.1155/2015/137136] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
531 Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol 2013;29:44-54. [PMID: 23700570 DOI: 10.3393/ac.2013.29.2.44] [Reference Citation Analysis]
532 Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One 2012;7:e36979. [PMID: 22761653 DOI: 10.1371/journal.pone.0036979] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
533 Blocker SJ, Shields AF. Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 2018;20:340-51. [PMID: 29188418 DOI: 10.1007/s11307-017-1142-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
534 de Mestier L, Manceau G, Neuzillet C, Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouché O, Hannoun L, Karoui M. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World J Gastrointest Oncol 2014;6:156-69. [PMID: 24936226 DOI: 10.4251/wjgo.v6.i6.156] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
535 O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96:189-195. [PMID: 17211479 DOI: 10.1038/sj.bjc.6603515] [Cited by in Crossref: 370] [Cited by in F6Publishing: 299] [Article Influence: 26.4] [Reference Citation Analysis]
536 Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981-986. [PMID: 20160718 DOI: 10.1038/sj.bjc.6605580] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 7.9] [Reference Citation Analysis]
537 Hassid Y, Eyal E, Margalit R, Furman-Haran E, Degani H. Non-invasive imaging of barriers to drug delivery in tumors. Microvasc Res 2008;76:94-103. [PMID: 18638494 DOI: 10.1016/j.mvr.2008.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
538 Gavriilidis P, Tobias A, Sutcliffe RP, Azoulay D, Roberts KJ. Network Meta-Analysis of Adjuvant Chemotherapy following Resection of Colorectal Liver Metastases. Gastrointest Tumors 2018;5:21-31. [PMID: 30574478 DOI: 10.1159/000490763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
539 Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol 2016;11:293-308. [PMID: 26687849 DOI: 10.1007/s11523-015-0400-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
540 Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW Jr, Shultz DB, Le QT, Koong AC, Chang DT. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015;92:568-76. [PMID: 26068491 DOI: 10.1016/j.ijrobp.2015.02.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
541 Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol 2014;6:280-92. [PMID: 25364393 DOI: 10.1177/1758834014543794] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
542 Whisenant J, Bergsland E. Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol. 2005;6:411-421. [PMID: 16107244 DOI: 10.1007/s11864-005-0044-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
543 Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30. [PMID: 17462954 DOI: 10.1016/j.molmed.2007.04.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 87] [Article Influence: 7.3] [Reference Citation Analysis]
544 Kajizono M, Saito M, Maeda M, Yamaji K, Fujiwara S, Kawasaki Y, Matsunaga H, Sendo T. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer. Int J Clin Oncol 2013;18:684-8. [PMID: 22678464 DOI: 10.1007/s10147-012-0427-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 Ramiscal JA, Jatoi A. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients. Acta Oncol 2011;50:578-81. [PMID: 21108568 DOI: 10.3109/0284186X.2010.537692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
546 Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263-267. [PMID: 22162570 DOI: 10.1200/jco.2011.37.1039] [Cited by in Crossref: 333] [Cited by in F6Publishing: 110] [Article Influence: 33.3] [Reference Citation Analysis]
547 Angiolini F, Cavallaro U. The Pleiotropic Role of L1CAM in Tumor Vasculature. Int J Mol Sci 2017;18:E254. [PMID: 28134764 DOI: 10.3390/ijms18020254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
548 Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218. [PMID: 19333227 DOI: 10.1038/nrclinonc.2009.16] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
549 Chung TW, Kim EY, Choi HJ, Han CW, Jang SB, Kim KJ, Jin L, Koh YJ, Ha KT. 6'-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis. Exp Mol Med 2019;51:1-13. [PMID: 31604908 DOI: 10.1038/s12276-019-0311-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
550 Francescone R, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 2012;287:24821-31. [PMID: 22654102 DOI: 10.1074/jbc.M111.334540] [Cited by in Crossref: 95] [Cited by in F6Publishing: 62] [Article Influence: 10.6] [Reference Citation Analysis]
551 Feng J, Yang Y, Zhang P, Wang F, Ma Y, Qin H, Wang Y. miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb. J Cell Mol Med 2014;18:2125-34. [PMID: 25230975 DOI: 10.1111/jcmm.12398] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
552 Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol. 2010;11:1-13. [PMID: 20143276 DOI: 10.1007/s11864-010-0115-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
553 Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015;6:60-74. [PMID: 25642339 DOI: 10.3978/j.issn.2078-6891.2014.098] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
554 Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011;12:169-80. [PMID: 21617380 DOI: 10.4161/cbt.12.3.16260] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
555 Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol 2013;29:44-54. [PMID: 23700570 DOI: 10.3393/ac.2013.29.2.44] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
556 Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804-1809. [PMID: 20150572 DOI: 10.1093/annonc/mdq020] [Cited by in Crossref: 422] [Cited by in F6Publishing: 362] [Article Influence: 38.4] [Reference Citation Analysis]
557 Kim EJ, Woo HS, Cho JH, Sym SJ, Baek JH, Lee WS, Kwon KA, Kim KO, Chung JW, Park DK, Kim YJ. Early experience with Watson for oncology in Korean patients with colorectal cancer. PLoS One 2019;14:e0213640. [PMID: 30908530 DOI: 10.1371/journal.pone.0213640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
558 Le QT, Raben D. Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Semin Radiat Oncol 2009;19:53-62. [PMID: 19028346 DOI: 10.1016/j.semradonc.2008.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
559 Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol. 2015;20:767-775. [PMID: 25627820 DOI: 10.1007/s10147-015-0784-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
560 Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, Shureiqi I. 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med. 2014;3:472-484. [PMID: 24634093 DOI: 10.1002/cam4.222] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
561 Knieling F, Waldner MJ, Goertz RS, Strobel D. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Rep. 2012;2012. [PMID: 23257272 DOI: 10.1136/bcr-2012-007576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
562 Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, Martini G, Ciardiello D, Cuadra JL, Tabernero J, Élez E. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:1758835921992974. [PMID: 33747149 DOI: 10.1177/1758835921992974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
563 Andreuzzi E, Capuano A, Poletto E, Pivetta E, Fejza A, Favero A, Doliana R, Cannizzaro R, Spessotto P, Mongiat M. Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis. Int J Mol Sci 2020;21:E3686. [PMID: 32456248 DOI: 10.3390/ijms21103686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
564 Hackl C, Gerken M, Loss M, Klinkhammer-schalke M, Piso P, Schlitt HJ. A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany. Int J Colorectal Dis 2011;26:1475-81. [DOI: 10.1007/s00384-011-1278-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
565 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
566 Thüring J, Kuhl CK, Barabasch A, Hitpass L, Bode M, Bünting N, Bruners P, Krämer NA. Signal changes in T2-weighted MRI of liver metastases under bevacizumab-A practical imaging biomarker? PLoS One 2020;15:e0230553. [PMID: 32231380 DOI: 10.1371/journal.pone.0230553] [Reference Citation Analysis]
567 Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 2014;111:1241-8. [PMID: 25117820 DOI: 10.1038/bjc.2014.430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
568 Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose D, Ramachandran V, Ellis LM. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 2011;104:1270-7. [PMID: 21407219 DOI: 10.1038/bjc.2011.81] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 6.2] [Reference Citation Analysis]
569 Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 2011;30:561-574. [PMID: 20956938 DOI: 10.1038/onc.2010.430] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 8.3] [Reference Citation Analysis]
570 Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009;4:67-76. [PMID: 19373440 DOI: 10.1007/s11523-009-0106-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
571 Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer 2013;13:120. [PMID: 23497305 DOI: 10.1186/1471-2407-13-120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
572 Janne d'Othée B, Sofocleous CT, Hanna N, Lewandowski RJ, Soulen MC, Vauthey JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol 2012;23:153-63. [PMID: 22264550 DOI: 10.1016/j.jvir.2011.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
573 Osawa T, Muramatsu M, Wang F, Tsuchida R, Kodama T, Minami T, Shibuya M. Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis. Proc Natl Acad Sci U S A 2011;108:20725-9. [PMID: 22143793 DOI: 10.1073/pnas.1108462109] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
574 Buchler T, Pavlik T, Melichar B, Bortlicek Z, Usiakova Z, Dusek L, Kiss I, Kohoutek M, Benesova V, Vyzula R, Abrahamova J, Obermannova R. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer 2014;14:323. [PMID: 24884897 DOI: 10.1186/1471-2407-14-323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
575 Davidson M, Smyth EC, Cunningham D. Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma. Onco Targets Ther. 2016;9:4539-4548. [PMID: 27524910 DOI: 10.2147/ott.s84153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
576 Sharma A, Low J, Mrugala MM. Neuro-oncologists have spoken - the role of bevacizumab in the inpatient setting. A clinical and economic conundrum. Neurooncol Pract 2019;6:30-6. [PMID: 31385984 DOI: 10.1093/nop/npy011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
577 Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010;16:5320-8. [PMID: 21041183 DOI: 10.1158/1078-0432.CCR-10-0974] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
578 Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 2015;20:166-75. [PMID: 25568148 DOI: 10.1634/theoncologist.2014-0330] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
579 Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther 2011;12:1032-49. [PMID: 22157148 DOI: 10.4161/cbt.12.12.18442] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
580 Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071-1121. [PMID: 21742796 DOI: 10.1152/physrev.00038.2010] [Cited by in Crossref: 887] [Cited by in F6Publishing: 771] [Article Influence: 88.7] [Reference Citation Analysis]
581 Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Manag Res. 2015;7:165-173. [PMID: 26109878 DOI: 10.2147/cmar.s61408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
582 Edrei Y, Gross E, Corchia N, Abramovitch R. Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer. 2012;107:658-666. [PMID: 22805330 DOI: 10.1038/bjc.2012.322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
583 Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J. New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis. Cancers (Basel) 2021;13:3253. [PMID: 34209679 DOI: 10.3390/cancers13133253] [Reference Citation Analysis]
584 Matsumoto M, Roufail S, Inder R, Caesar C, Karnezis T, Shayan R, Farnsworth RH, Sato T, Achen MG, Mann GB. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis. 2013;30:819-832. [PMID: 23591595 DOI: 10.1007/s10585-013-9581-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
585 Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083-1090. [PMID: 21263087 DOI: 10.1200/jco.2010.32.6132] [Cited by in Crossref: 256] [Cited by in F6Publishing: 89] [Article Influence: 25.6] [Reference Citation Analysis]
586 Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H. Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells. World J Gastroenterol. 2005;11:5638-5643. [PMID: 16237757 DOI: 10.3748/wjg.v11.i36.5638] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
587 Zhu GQ, You J, Shi KQ, He SY, Wang LR, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. Medicine (Baltimore) 2015;94:e379. [PMID: 25569666 DOI: 10.1097/MD.0000000000000379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
588 Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol 2016;18:173-83. [PMID: 26627848 DOI: 10.1093/neuonc/nov288] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
589 Hanna DL, Lenz HJ. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Rev Clin Pharmacol 2016;9:1091-108. [PMID: 27031164 DOI: 10.1586/17512433.2016.1172961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
590 Rice C, Huang LE. From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res 2010;3:9-16. [PMID: 21407995 DOI: 10.2147/CMR.S14812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
591 Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418-425. [PMID: 18087285 DOI: 10.1038/sj.bjc.6604129] [Cited by in Crossref: 240] [Cited by in F6Publishing: 220] [Article Influence: 17.1] [Reference Citation Analysis]
592 Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer. 2012;107:1932-1937. [PMID: 23169296 DOI: 10.1038/bjc.2012.509] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
593 Kim ST, Jang KT, Lee J, Jang HM, Choi HJ, Jang HL, Park SH, Park YS, Lim HY, Kang WK, Park JO. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol 2015;8:40-6. [PMID: 25749176 DOI: 10.1016/j.tranon.2014.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
594 Cameron AC, Touyz RM, Lang NN. Vascular Complications of Cancer Chemotherapy. Can J Cardiol 2016;32:852-62. [PMID: 26968393 DOI: 10.1016/j.cjca.2015.12.023] [Cited by in Crossref: 81] [Cited by in F6Publishing: 58] [Article Influence: 13.5] [Reference Citation Analysis]
595 Wang CC, Liang JT, Tsai CL, Chen YH, Lin YL, Shun CT, Cheng JC. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World J Surg Oncol 2014;12:329. [PMID: 25373828 DOI: 10.1186/1477-7819-12-329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
596 Stegh AH. Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) 2013;5:48-65. [PMID: 22858688 DOI: 10.1039/c2ib20104f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
597 Sugimoto S, Katano K, Kanazawa A, Yoshimura H, Kidani A, Takeda H, Makino M, Ozaki N, Tanaka T, Ikeguchi M. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. J Exp Clin Cancer Res 2009;28:109. [PMID: 19664225 DOI: 10.1186/1756-9966-28-109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
598 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
599 Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol 2011;7:1383-94. [PMID: 21978383 DOI: 10.1517/17425255.2011.609555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
600 Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453-459. [PMID: 20008624 DOI: 10.1200/jco.2009.24.8252] [Cited by in Crossref: 347] [Cited by in F6Publishing: 160] [Article Influence: 28.9] [Reference Citation Analysis]
601 Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8:73009-73016. [PMID: 29069844 DOI: 10.18632/oncotarget.20314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
602 Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010;30:229-41. [PMID: 20225906 DOI: 10.2165/11532260-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
603 Jarzyna PA, Deddens LH, Kann BH, Ramachandran S, Calcagno C, Chen W, Gianella A, Dijkhuizen RM, Griffioen AW, Fayad ZA, Mulder WJ. Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging. Neoplasia 2012;14:964-73. [PMID: 23097630 DOI: 10.1593/neo.121148] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
604 Nasser NJ, Fox J, Agbarya A. Potential Mechanisms of Cancer-Related Hypercoagulability. Cancers (Basel) 2020;12:E566. [PMID: 32121387 DOI: 10.3390/cancers12030566] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
605 Yoon YS, Kim JC. Recent applications of chemosensitivity tests for colorectal cancer treatment. World J Gastroenterol 2014;20:16398-408. [PMID: 25469008 DOI: 10.3748/wjg.v20.i44.16398] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
606 Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009;20:413-24. [PMID: 19088170 DOI: 10.1093/annonc/mdn666] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
607 Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 2015;112:650-9. [PMID: 25625276 DOI: 10.1038/bjc.2014.653] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
608 Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. Onco Targets Ther 2019;12:2159-70. [PMID: 30988620 DOI: 10.2147/OTT.S194745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
609 Peifer M, Weiss J, Sos ML, Koker M, Heynck S, Netzer C, Fischer S, Rode H, Rauh D, Rahnenführer J, Thomas RK. Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS One 2010;5:e8919. [PMID: 20111714 DOI: 10.1371/journal.pone.0008919] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
610 Mohile SG, Hardt M, Tew W, Owusu C, Klepin H, Gross C, Gajra A, Lichtman SM, Feng T, Togawa K, Ramani R, Katheria V, Hansen K, Hurria A; Cancer and Aging Research Group. Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist 2013;18:408-14. [PMID: 23576485 DOI: 10.1634/theoncologist.2012-0351] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
611 Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513-8. [PMID: 24419115 DOI: 10.1200/JCO.2013.51.7904] [Cited by in Crossref: 272] [Cited by in F6Publishing: 93] [Article Influence: 38.9] [Reference Citation Analysis]
612 Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008;198:477.e1-9; discussion 477.e9-10. [PMID: 18395047 DOI: 10.1016/j.ajog.2007.12.028] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
613 Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist. 2011;16:1131-1137. [PMID: 21795432 DOI: 10.1634/theoncologist.2011-0078] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
614 Xu J, Fan J, Qin X, Cai J, Gu J, Wang S, Wang X, Zhang S, Zhang Z; China CRLM Guideline Group. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol. 2019;145:725-736. [PMID: 30542791 DOI: 10.1007/s00432-018-2795-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
615 Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117:1296-1301. [PMID: 21381016 DOI: 10.1002/cncr.25573] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
616 Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008;9:201. [PMID: 18447899 DOI: 10.1186/1471-2164-9-201] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
617 Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222-243. [PMID: 20554717 DOI: 10.3322/caac.20075] [Cited by in Crossref: 311] [Cited by in F6Publishing: 243] [Article Influence: 28.3] [Reference Citation Analysis]
618 Zhao S, Huang J, Ye J. A fresh look at zebrafish from the perspective of cancer research. J Exp Clin Cancer Res 2015;34:80. [PMID: 26260237 DOI: 10.1186/s13046-015-0196-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 9.7] [Reference Citation Analysis]
619 Ong FS, Kuo JZ, Wu WC, Cheng CY, Blackwell WL, Taylor BL, Grody WW, Rotter JI, Lai CC, Wong TY. Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. J Pers Med 2013;3:40-69. [PMID: 24624293 DOI: 10.3390/jpm3010040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
620 Giampieri R, Puzzoni M, Daniele B, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Pella N, Zampino MG, Sozzi P, Germano D, Zagonel V, Codecà C, Libertini M, Labianca R, Cascinu S, Scartozzi M; Italian Group for the Study of Gastrointestinal Cancer (GISCAD). First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. Br J Cancer 2017;117:1099-104. [PMID: 28926529 DOI: 10.1038/bjc.2017.234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
621 Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ. Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One 2010;5:e13699. [PMID: 21060881 DOI: 10.1371/journal.pone.0013699] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
622 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 57] [Article Influence: 12.8] [Reference Citation Analysis]
623 Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17:372-81. [PMID: 21224365 DOI: 10.1158/1078-0432.CCR-10-1791] [Cited by in Crossref: 77] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
624 Lassen U, Nielsen DL, Sørensen M, Winstedt L, Niskanen T, Stenberg Y, Pakola S, Stassen JM, Glazer S. A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer 2012;106:678-84. [PMID: 22333707 DOI: 10.1038/bjc.2011.609] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
625 Tsoi M, Laguë MN, Boyer A, Paquet M, Nadeau MÈ, Boerboom D. Anti-VEGFA Therapy Reduces Tumor Growth and Extends Survival in a Murine Model of Ovarian Granulosa Cell Tumor. Transl Oncol 2013;6:226-33. [PMID: 23730402 DOI: 10.1593/tlo.13136] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
626 Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterol. 2015;15:37. [PMID: 25888291 DOI: 10.1186/s12876-015-0266-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
627 Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 2014;5:10280-92. [PMID: 25373733 DOI: 10.18632/oncotarget.2163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
628 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015;9:3099-108. [PMID: 26124634 DOI: 10.2147/DDDT.S85567] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
629 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
630 Shekelle PG, Ortiz E, Newberry SJ, Rich MW, Rhodes SL, Brook RH, Goldman DP. Identifying potential health care innovations for the future elderly. Health Aff (Millwood) 2005;24 Suppl 2:W5R67-76. [PMID: 16186152 DOI: 10.1377/hlthaff.w5.r67] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
631 Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer 2017;17:243. [PMID: 28376737 DOI: 10.1186/s12885-017-3245-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
632 Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012;7:e38231. [PMID: 22701615 DOI: 10.1371/journal.pone.0038231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
633 Johnpulle RA, Johnson DB, Sosman JA. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr Oncol Rep 2016;18:6. [PMID: 26743513 DOI: 10.1007/s11912-015-0485-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
634 Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer 2017;116:600-8. [PMID: 28141797 DOI: 10.1038/bjc.2017.13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
635 Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26:2839-2845. [PMID: 18539962 DOI: 10.1200/jco.2007.15.1829] [Cited by in Crossref: 490] [Cited by in F6Publishing: 251] [Article Influence: 37.7] [Reference Citation Analysis]
636 Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.J Gastrointest Oncol. 2016;7:45-57. [PMID: 26941983 DOI: 10.3978/j.issn.2078-6891.2015.111] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
637 Fontenot E, Rossi E, Mumper R, Snyder S, Siamakpour-Reihani S, Ma P, Hilliard E, Bone B, Ketelsen D, Santos C, Patterson C, Klauber-DeMore N. A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. Mol Cancer Ther 2013;12:685-95. [PMID: 23604067 DOI: 10.1158/1535-7163.MCT-12-1066] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
638 Zhang J, Liu J. Tumor stroma as targets for cancer therapy. Pharmacol Ther 2013;137:200-15. [PMID: 23064233 DOI: 10.1016/j.pharmthera.2012.10.003] [Cited by in Crossref: 126] [Cited by in F6Publishing: 111] [Article Influence: 14.0] [Reference Citation Analysis]
639 Klegerman ME, Naji AK, Haworth KJ, Zou Y, Golunski E, Peng T, Britton GL, Huang SL, Holland CK, McPherson DD. Ultrasound-enhanced bevacizumab release from echogenic liposomes for inhibition of atheroma progression. J Liposome Res 2016;26:47-56. [PMID: 25865025 DOI: 10.3109/08982104.2015.1029494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
640 Berdel WE. Unintended Regulatory Caused Early Death-A Difficult Endpoint in Cancer Patient Care and Treatment. Cancers (Basel) 2021;13:1457. [PMID: 33810203 DOI: 10.3390/cancers13061457] [Reference Citation Analysis]
641 Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol. 2014;20:4536-4545. [PMID: 24782606 DOI: 10.3748/wjg.v20.i16.4536] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
642 Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer 2013;119:4180-7. [PMID: 24104527 DOI: 10.1002/cncr.28343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
643 Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM, Xie DR. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Gastroenterol Res Pract 2014;2014:594930. [PMID: 24971091 DOI: 10.1155/2014/594930] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
644 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
645 Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010;102 Suppl 1:S2-9. [PMID: 20386546 DOI: 10.1038/sj.bjc.6605599] [Cited by in Crossref: 212] [Cited by in F6Publishing: 170] [Article Influence: 19.3] [Reference Citation Analysis]
646 Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC. Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2011;128:2663-72. [PMID: 20715106 DOI: 10.1002/ijc.25609] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
647 Montemagno C, Pagès G. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front Cell Dev Biol 2020;8:584. [PMID: 32775327 DOI: 10.3389/fcell.2020.00584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
648 Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:2222-2229. [PMID: 21054149 DOI: 10.3109/10428194.2010.524327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
649 Makondi PT, Lee CH, Huang CY, Chu CM, Chang YJ, Wei PL. Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer. PLoS One 2018;13:e0189582. [PMID: 29342159 DOI: 10.1371/journal.pone.0189582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
650 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
651 Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73. [PMID: 18772115 DOI: 10.1016/j.ccr.2008.08.001] [Cited by in Crossref: 336] [Cited by in F6Publishing: 285] [Article Influence: 25.8] [Reference Citation Analysis]
652 López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010;103:1536-41. [PMID: 20940719 DOI: 10.1038/sj.bjc.6605938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
653 de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension 2012;60:607-15. [PMID: 22851729 DOI: 10.1161/HYPERTENSIONAHA.112.196774] [Cited by in Crossref: 76] [Cited by in F6Publishing: 25] [Article Influence: 8.4] [Reference Citation Analysis]
654 Velpandian T, Sharma C, Garg SP, Mandal S, Ghose S. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian J Ophthalmol 2007;55:488-90. [PMID: 17951922 DOI: 10.4103/0301-4738.36502] [Cited by in Crossref: 5] [